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“If written in the three-letter words of the four-letter alphabet, a human being is determined 
by a genetic narrative long enough to fill the equivalent of 500 Bibles. In the meantime 
human beings have discovered this for themselves. That’s right. They have uncovered our 
profoundest concept – namely, that life is ultimately reading. They themselves are the Book 
of Books.” 
– Harry Mulisch, The Discovery of Heaven, 1992 
 
  
ABSTRACT 
Atherosclerosis and its clinical sequelae remain a world leading cause of disease and death, 
despite recent advances in primary and secondary prevention. The silently progressive 
character of the disease, in combination with the influence of individual patient 
characteristics, makes acute events difficult to predict and prevent. There is a need for (1) 
noninvasive, accurate diagnostic methods and (2) individually tailored therapies, in order to 
provide effective treatment whilst avoiding unnecessary interventions and iatrogenic damage. 
In the search for novel detection methods and drugs, non-coding RNA has emerged as a class 
of important biological regulators, being crucially involved in virtually every cellular process. 
We show that patients at risk for cardiovascular events display characteristic non-coding 
RNA patterns and could be treated with RNA interference (RNAi) therapy, targeting and 
normalizing previously ‘undruggable’ physiological disruptions. 
In order to measure up to these high expectations, findings from basic non-coding 
RNA research need to be applied in (pre-)clinical studies. MicroRNAs (miRNA, miR) have 
been demonstrated to be modifiers of cardiovascular disease via posttranscriptional inhibition 
of messenger RNA. In this thesis, in vitro as well as in vivo modulation of clinically relevant 
miRNAs are presented as a therapeutic approach to alter vascular cell behavior and induce 
reparative arterial remodeling in three cardiovascular diseases (stroke, abdominal aortic 
aneurysm (AAA) and radiation-induced vasculopathy). In two different mouse models of 
AAA, we showed that miR-24 treatment hampers AAA expansion. Cell and human tissue 
experiments demonstrated a positive effect of miR-24 that could be attributed to an inhibitory 
action of this miRNA on chitinase 3-like 1, a marker of macrophage-induced inflammation. 
In AAA, a disease for which screening has been suggested but fails to meet socioeconomic 
demands, we are the first to present a sufficiently powered biomarker study, where miR-99b, 
detected in the circulation, could predict aneurysm expansion and rupture risk. In patients 
with carotid artery atherosclerosis at risk for stroke, miR-210 was decreased in the 
atherosclerotic fibrous cap. In vivo experiments of murine carotid injury and plaque rupture 
showed that low expression of miR-210 was associated with fibrous cap smooth muscle cell 
apoptosis through adenomatous polyposis coli, and that miR-210 treatment could prevent 
carotid plaque rupture in mice. In chronic arterial inflammation secondary to radiotherapy, 
miR-29b deregulation demonstrated an adverse inflammatory and fibrotic response, which in 
mice could be corrected with miR-29b mimic therapy, partly through a restored inhibition of 
miR-29b targets pentraxin 3 and dipeptidyl-peptidase 4.  
Our approaches have not only revealed possible diagnostic and therapeutic use of 
non-coding RNAs, but have also presented us with the difficulties and limitations of 
presenting exogenous RNA modifiers to a diseased circulatory system. Distribution, efficacy, 
off-target effects, and pleiotropy are issues that need to be addressed before non-coding 
RNAi therapy can be exploited clinically.  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hjärt- och kärlsjukdomar fortsätter att vara en världsledande orsak till sjukdom och 
mortalitet, trots en ständig förbättring av behandling såväl som prevention. Det kvarstår 
därför ett stort behov av (1) metoder för at fastställa diagnos på ett tidigt stadium, och (2) 
individuell terapi. Som ett led i att utforska nya diagnostiska metoder samt behandling, har 
icke-kodande RNA nyligen upptäckts som en klass av viktiga biologiska regulatorer vilka har 
en viktig funktion i nästan alla mänskliga cellulära processer. I denna avhandling visas att 
patienter som har hög risk för att utveckla hjärt- och kärlsjukdomar, uppvisar särskilda 
förändringar i sitt icke-kodande RNA. Dessa förändringar skulle potentiellt kunna korrigeras 
genom så kallad RNA-interferens-terapi (RNAi) och därigenom dämpa 
sjukdomsutvecklingen i hjärt- och kärlsystemet via vägar som inte kan nås med traditionell 
behandling. 
MicroRNA (miRNA, miR) utgör en klass av icke-kodande RNA som har visats 
besitta potentialen att förbättra men även försämra hjärt- och kärlsjukdomar. Detta gör de 
genom att reglera mängden budbärar- (messenger) RNA som i sin tur förmedlar aktivitet av 
gener. För tre olika sjukdomar (hjärninfarkt, bukaortaaneurysm (AAA) samt 
strålningsinducerad vaskulit) visar vi med hjälp av odlade celler och djurstudier, att kliniskt 
relevanta miRNAs kan påverkas utifrån för att influera cellers beteende och initiera 
reparation av kärlväggen. I två olika musmodeller av AAA demonstrerade vi att miR-24 
hindrar utvidgning av aneurysm. Vidare experiment i celler och human vävnad visade att den 
positiva effekten av miR-24 delvis kan tillskrivas en minskning av chitinase 3-like 1, ett 
protein som vidhåller kärlväggsinflammationen. För AAA, en allvarlig sjukdom för vilken 
befintliga screeningmetoder i nuläget inte är genomförbara utifrån ett socioekonomiskt 
perspektiv, visade vi att uppmätta nivåer av miR-99b i blodet kunde bidra till att förutspå 
utvidgning och ruptur. I patienter med åderförkalkning i halspulsådern och en förhöjd risk för 
stroke, observerade vi en minskad mängd miR-210 i glattmuskelceller i 
åderförkalkningsplackens skyddande kapsel. Musexperiment visade att miR-210-terapi kan 
blockera uttrycket av proteinet adenomatous polyposis coli, vilket förebygger 
glattmuskelcellernas död och därigenom stabiliserar kapseln. I kroniskt inflammerad vävnad 
från uttagen pulsåder som tidigare utsatts för joniserande strålning, såg vi en minskning av 
miR-29b. miR-29b är viktig för att förhindra inflammation och förebygga ärrbildning. I möss 
kunde vi korrigera bristen av miR-29b vilket därigenom ledde till minskning av 
inflammationsproteinerna pentraxin 3 och dipeptidyl-peptidase 4. 
Vårt arbete visar att särskilda icke-kodande RNA kan bidra både till en potentiellt 
förbättrad diagnostik och behandling. Dock har våra studier också gjort os varse om 
begränsningar som denna vetenskap medför, teoretisk och praktiskt. Innan det blir möjligt att 
överföra RNAi-terapi till kliniken måste medicinernas effektivitet och möjliga biverkningar 
utforskas vidare. 
  
  
SAMENVATTING 
Ondanks dat atherosclerose (vaatverkalking) steeds beter voorkomen en behandeld kan 
worden, blijven atherosclerotische aandoeningen, in de vorm van hart- en vaatziekten, ‘s 
werelds belangrijkste bron van ziekte en sterfte. Er is behoefte aan (1) methoden om de ziekte 
vast te stellen zonder de patiënt schade te berokkenen, en (2) op het individu toegespitste 
therapieën. In de zoektocht naar nieuwe detectiemethoden en medicatie is recent niet-
coderend RNA ontdekt als een groep belangrijke biologische regulatoren, die van cruciaal 
belang is in zo goed als alle menselijke cellulaire processen. Wij toonden aan dat patiënten 
met een risico op hart- en vaatziekten een karakteristiek patroon van veranderingen in het 
niet-coderend RNA vertonen, en dat zij behandeld kunnen worden met zogenoemde RNA-
interferentie (RNAi)-therapie, die de ziekmakende verstoringen van het hart- en vaatsysteem 
aanpakt via wegen die met traditionele medicijnen niet bereikt kunnen worden. 
MicroRNAs (miRNA, miR) vormen een klasse van niet-coderend RNA die sinds 
enkele decennia steeds beter bekend is komen te staan als een groep moleculen die hart- en 
vaatziekten kan beïnvloeden door het boodschapper- (messenger) RNA, dat signalen vanuit 
de celkern naar de cel doorgeeft, direct tegen te werken of te vernietigen. Voor drie ziekten 
(herseninfarct, aneurysma van de abdominale aorta (AAA) en stralingsgeïnduceerde 
vasculitis (vRTx)) laten we op cellulair niveau en in dieronderzoek zien dat bepaalde klinisch 
relevante miRNAs van buitenaf gereguleerd kunnen worden om zo het gedrag van cellen te 
kunnen beïnvloeden en herstel van de vaatwand te bevorderen. In twee verschillende 
muismodellen van AAA demonstreren we dat miR-24 het uitdijen van een aneurysma remt. 
Experimenten in cellen en op humaan weefsel lieten zien dat het positieve effect van miR-24 
toe te schrijven was aan remming door miR-24 van chitinase 3-like 1, een eiwit dat de 
ontstekingsreactie in de vaatwand in stand houdt. Wij presenteren tevens de eerste studie 
waaraan voldoende AAA-patiënten meededen om voor grote groepen patiënten aan te tonen 
dat de hoeveelheid miR-99b, gemeten in het bloed, kan bijdragen aan het voorspellen van 
uitdijing en barsten van een AAA. In patiënten met atherosclerose van de halsslagader en een 
hoog risico op herseninfarct zagen we verminderde expressie van miR-210 in de gladde 
spiercellen van de fibreuze kap van de atherosclerotische plaque. Muisexperimenten toonden 
aan dat miR-210-therapie de fibreuze kap kan stabiliseren, door celdood van gladde-
spiercellen te voorkomen middels remming van het eiwit adenomatous polyposis coli. In 
chronisch ontstoken weefsel van slagaders blootgesteld aan radiotherapie zagen we dat miR-
29b verminderd was. miR-29b is belangrijk voor het remmen van ontsteking en het 
voorkomen van de vorming van littekenweefsel. In muizen kon het gebrek aan miR-29b 
worden gecorrigeerd, hetgeen leidde tot remming van de ontstekingseiwitten pentraxin 3 en 
dipeptidyl-peptidase 4. 
Met ons werk hebben wij laten zien dat bepaalde niet-coderende RNAs kunnen 
bijdragen aan diagnostiek en behandeling, maar ook dat het blootstellen van een ziek hart- en 
vaatstelsel aan RNAi-therapie moeilijkheden en beperkingen met zich meebrengt. Voordat 
deze vorm van behandeling klinisch toegepast kan worden, moeten het gedrag, de effectiviteit 
en de bijwerkingen van RNAi-therapie verder worden onderzocht.  
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1 INTRODUCTION 
 
1.1 ATHEROSCLEROSIS 
Atherosclerosis is defined as thickening and loss of elasticity of the inner lining of arteries. In 
humans, this biological process is part of normal aging1,2. Atherosclerosis is initiated early in 
life3,4 and characterized by the development of arterial lesions commonly referred to as 
plaques or atheromas. Plaque development has various stages, of which most are clinically 
silent. Only when plaque-derived stenoses become flow-limiting, that is, in the very last 
stage of the disease, they manifest as cardiovascular disease5. Disruption of arterial blood 
flow means that tissue becomes deprived of oxygen and nutrients, which leads to cell death, 
inflammation and organ dysfunction. Examples of clinical consequences are stroke and 
myocardial infarction, which together account for a third of all deaths worldwide6. The 
classical view that cardiovascular disease is a problem of wealth is outdated; 80% of 
cardiovascular deaths occur in low- and middle-income countries7. Despite immense efforts 
from the medical and scientific communities, the worldwide hegemony of cardiovascular 
disease as the most important cause of death has to date not been halted. 
The strongest risk factors for cardiovascular disease are age, gender, smoking, low density 
lipoprotein (LDL) cholesterol levels and blood pressure8. Some of these are modifiable with 
life style interventions, measures that can have an important effect on a population scale. The 
deployment of statins has further improved cardiovascular disease prevention: by lowering 
LDL cholesterol, statins are effective in reducing risk of myocardial infarction and stroke9. In 
large trials including patients with hypertension, blood pressure lowering by blocking of the 
renin-angiotensin-aldosterone system (RAAS) has shown to reduce cardiovascular morbidity 
as well as all-cause mortality10. Both of these successful treatments are directed towards 
early changes in atherosclerosis development, and for many people at high risk of 
cardiovascular disease, with advanced atherosclerotic plaque formation but no symptoms, 
these treatments may offer too little too late. This, as well as the availability of a rapidly 
growing arsenal of medication and invasive procedures (percutaneous revascularizations, 
endarterectomy) calls for individually tailored diagnosis and therapy. Especially in a patient 
population at high cardiovascular risk – the elderly – treatment risks may outweigh possible 
benefits11. Present-day ‘personalized medicine’ originates from these demands. Our work 
aims to contribute to finding new diagnostic and treatment methods that are less invasive, 
and more effective, in predicting and preventing cardiovascular disease, and at the same time 
limit an atherosclerosis carrier’s risk for (further) disease manifestations while reducing 
overtreatment, an approach essential to harness escalating healthcare costs. 
1.1.1 Pathologic basis of atherosclerosis 
The least controversial and best understood risk factor for atherosclerosis is a disordered 
plasma lipid content (dyslipidemia), especially a high concentration of LDL cholesterol12. 
The innermost layer of the vessel wall, the intima, has the ability to retain lipoproteins 
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derived from circulating blood. A high plasma lipoprotein content leads to increased intimal 
uptake, likely through binding with enzymes and proteoglycans13 on the surface of 
endothelial cells (ECs) that form the interior lining of the vessel14. Intimal accumulations of 
LDL cholesterol oxidize and activate resident macrophages by stimulation of scavenger 
receptors15. Macrophages engulf and opsonize the modified lipids. When cholesterol influx 
exceeds efflux, the cells become ‘lipid laden’. This lipid loading of macrophages transforms 
them into cells with a foamy appearance, hence the name ‘foam cells’. At predilection sites 
for atherosclerosis, or atheroprone regions, intimal accumulation of foam cells results in the 
formation of fatty streaks, macroscopically discernible areas with a high lipid content. 
Atheroprone regions have an impaired endothelial coverage and function16, as well as a 
higher tendency to retain LDL particles. LDL cholesterol, when aggregated and oxidized in 
the arterial wall, is recognized and reacted upon by cells of the immune system, sparking a 
chronic inflammatory reaction17. 
Biomechanistically, atheroprone regions are characterized by a triad of properties: low shear 
stress, a high oscillatory shear index, and steep temporal and spatial gradients in shear 
stress18. Fluid shear stress in arteries is defined as the force inflicted on the vessel wall by the 
blood flowing parallel to it, and is dependent on blood viscosity and velocity. At sites 
exposed to a favorable shear stress, atherosclerosis rarely occurs. ECs directly exposed to the 
local shear stress, have important sensory functions for humoral as well as mechanic 
circulatory signals. Early atherosclerosis impairs the integrity of the EC layer, and the 
damage exposes the underlying cells, such as smooth muscle cells (SMCs), to the 
circulation16. 
During most of its development, atherosclerotic plaque does not cause any symptoms until 
the affected vessel becomes significantly narrowed (e.g. in angina pectoris) or occluded (e.g. 
in myocardial infarction). Slowly developing plaques may, through transitory periods of 
ischemia, induce the transformation of minor vessels into collaterals. This creates a natural 
bypass around the lesion19. 
The Atherosclerosis Council of the American Heart Association distinguishes six 
histological types of atherosclerotic lesions, only three of which are considered at risk to 
become clinically overt20. Throughout plaque development, the growing lipid core is 
separated from the vascular lumen by a collagen-rich fibrous cap (Fig. 1.1B), and symptoms 
generally occur when the fibrous cap gets thinner and ruptures (Fig. 1.1C). This exposes the 
highly thrombogenic lipid core to blood coagulant factors, which triggers thrombus 
formation. Thrombi cause ischemic symptoms, of which the severity depends on thrombus 
size; smaller thrombi may initiate a healing response similar to the process occurring in skin 
lesions, including the formation of a scar-like, protective fibrous cap de novo21. Plaques at 
risk of rupture (also called vulnerable or unstable) can with increasing accuracy be detected 
with imaging methods22,23. To induce a healing response in vulnerable plaques without prior 
thrombus formation, through local distribution of cellular triggers of e.g. collagen formation, 
is a novel therapeutic approach to transform a vulnerable into a stable plaque. 
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As an atherosclerotic plaque develops, calcium can accumulate in the intimal and medial 
layers. Advanced plaque calcification is characterized by the presence of cells and proteins 
found in bone, such as osteoblasts, osteoclasts, osteopontin and bone morphogenic proteins 
(BMPs), and can even give the plaque a trabecular bone aspect. There is an increasing 
scientific interest in mechanisms underlying arterial calcification, and how it might 
contribute to plaque stabilization or –vulnerability24. 
 
Figure 1.1. Arterial atherosclerosis starts with 
(A) thickening of the intima (I) and narrowing of 
the lumen (L) as plasma lipoproteins are 
incorporated. Macrophages invade the lesion and 
opsonize oxidized LDL cholesterol. (B) Smooth 
muscle cells enter the intima and produce 
extracellular matrix, covering the growing lesion 
with a collagenous fibrous cap (FC) and creating 
a stable lesion. Oxidized LDL cholesterol 
augments expression of adhesive molecules by 
endothelial cells lining the vessel, facilitating 
adhesion and invasion of lymphocytes. This 
initiates an inflammatory reaction. (C), Top: 
Vulnerable lesion with a thin fibrous cap, a large 
lipid core, and increased influx of lymphocytes. 
Bottom: Ruptured lesion containing a damaged 
fibrous cap and a lipid core exposed to the vessel 
lumen, attracting coagulation factors and initiating 
thrombus formation.  
 
 
 
 
The most important producers of extracellular matrix in the fibrous cap are vascular smooth 
muscle cells (SMCs). SMCs form the medial layer of blood vessels. They originate from a 
variety of embryonic precursor cells distributed in a mosaic manner throughout the 
developing body. The boundaries of these embryonic cellular sources are poorly defined, 
making it difficult to map a single SMC to its individual origin25. In healthy arteries, the 
main function of SMCs is to maintain vessel tone and alter the luminal diameter, thereby 
regulating blood pressure. Under these physiologic conditions, SMCs are defined by 
expression of SMC-specific markers such as myocardin, smooth muscle cell myosin heavy 
chain (MYH11), smooth muscle α actin (ACTA2), and smoothelin (SMTN). The 
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transcription factor serum response factor (SRF), as well as the DNA modifying enzyme ten-
eleven translocation 2 (TET2), have been shown to induce this contractile phenotype26. In 
response to certain pathologic stimuli, such as hypoxia, disturbed blood flow, injury, or 
inflammation (e.g. in atherosclerosis), SMCs downregulate these characteristic markers and 
adopt a phenotype characterized by proliferation, migration, and altered extracellular matrix 
production27. This phenotypic transition is partly driven by Krüppel-like factor 4 (KLF4), a 
transcription factor indicating stem cell-like capacities of cells28, and platelet-derived growth 
factor (PDGF), a serum protein released by platelets and ECs which is strongly associated 
with cardiovascular disease29. Lipid accumulation in the plaque can even cause SMCs to 
adopt a macrophage-, almost foam cell-like phenotype, and as such stimulate progression of 
a plaque towards rupture30,31. Definitive analyses on whether these detrimental cell types 
derive from SMCs, macrophages, or other cell types, are still lacking; however, 
accumulating evidence suggests that these cells are indeed of SMC origin28,32. It is clear that 
induction of plaque stability involves the engagement of SMCs, although the appropriate 
signaling to and between these cells is required. This is one of many challenges in the 
development of targeted drugs and modifiers. 
Chronic inflammatory diseases, cardiovascular disease included, are characterized by an 
imbalance between inflammation and resolution of inflammation. Resolution is the 
capability of an organism to regulate and dampen the inflammatory response by the release 
of resolvins, factors that actively promote restoration of tissue morphology and function33. 
The fact that certain inflammatory signals can activate resolution, and that their blockage can 
lead to aggravation of the disease, highlights the ineffectiveness of simply blocking one 
agent or pathway in the inflammatory cell machinery. MicroRNAs, acting in network 
patterns, have a proven capability to influence multiple targets in the same pathway. 
Modulating them has shown to successfully tip the balance in favor of resolution. Especially 
the cardiovascular system, a tightly regulated network of spatially distant organs (kidney, 
heart, liver, intestine), is an excellent target for microRNA therapy34. 
1.2 CARDIOVASCULAR DISEASES STUDIED 
1.2.1 Abdominal aortic aneurysm 
A relatively uncommon, but striking example of vascular disease is abdominal aortic 
aneurysm (AAA), defined as an expansion of the abdominal aorta (Fig. 1.2A) more than 1.5 
times its size, or a diameter larger than 3 cm (Fig. 1.2B, left side). Risk factors for AAA 
largely overlap with those of atherosclerosis, with the exclusion of diabetes35. AAA cases 
seem to cluster within families, and although several genes have through genome-wide 
association studies (GWAS) been associated with the disease, no functional mechanism has 
yet been found to link any of these genes to the pathologic changes observed during the 
disease course36. An exception is the gene coding for cyclin-dependent kinase inhibitor 2B 
(CDKN2B)37, a tumor suppressor gene with an inhibitory action on p53 signaling. As of 
today, no systemic treatment exists to halt AAA development; AAA (including ruptured 
AAA) can only be corrected by implantation of a polymeric graft inside the aorta, either 
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surgically or with an endovascular procedure (endovascular aortic repair, EVAR). Open 
surgical repair is an invasive abdominal operation, where the dilated vessel is relieved of 
mechanic strain while being left in situ (Fig. 1.2C). The introduction of EVAR reduced the 
invasiveness of AAA correction, but not all aneurysms lend themselves to be treated with 
EVAR38. 
During AAA development, inflammation of the aortic wall, decreased SMC content, and 
disruption of the extracellular matrix cause weakening and loss of elasticity39. In concert 
with specific biomechanical forces40, these changes lead to a widening of the vessel. AAA 
typically remains asymptomatic until rupture occurs (Fig. 1.2B, right side), causing the aorta 
to drain directly in the abdominal cavity. Although a ruptured aneurysm may be temporarily 
‘contained’ by the surrounding retroperitoneal tissue, it is generally considered that the 
chance of surviving an untreated AAA rupture is null. Despite recent treatment advances, 
partly due to the introduction of EVAR, the overall mortality of AAA rupture remains 
between 80-90%41,42. The combination of poor prognosis and absence of clinical symptoms, 
and the possibility to screen for AAA noninvasively with ultrasound, has led to the initiation 
of screening programs in about a dozen countries, with Sweden and Great Britain at the 
forefront43. Still, AAAs are typically discovered as an incidental finding during radiologic 
examination of other conditions44. Barriers in the implementation of AAA screening are cost 
and infrastructure43, as well as the high number of AAA patients needed to be treated in 
order to prevent death due to rupture. The addition of identifiable circulating factors in the 
blood (‘biomarkers’) to current screening methods might provide a better prediction of 
rupture risk, thereby also increasing cost-effectiveness of AAA screening and leading to a 
better allocation of AAA repair surgery. 
 
Figure 1.2. AAA is defined as an expansion of the normal aorta (A) creating a balloon effect 
(B, left side). When the weakened vessel wall yields to internal mechanical pressure, rupture 
occurs (B, right side). (C) With a polymeric implant, the aortic wall is relieved from direct 
strain, thus preventing or treating rupture. 
1.2.2 Stroke 
Stroke is recognized as a disturbance of cerebral function due to a vascular cause. Around 
20% of strokes are caused by bleeding (hemorrhagic stroke), and 80% by occlusion 
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(ischemic stroke)45. In a cohort of 5017 patients with ischemic strokes, cardioembolism was 
the most common cause (25.6%), followed by carotid atherosclerosis (20.9%)46. In the 
context of this thesis, only the last form will be discussed. 
Stroke caused by carotid atherosclerosis generally originates from a ruptured plaque around 
the carotid bifurcation. Thrombi dislodging from the formed clot travel to smaller arteries in 
the brain, where they become occlusive and produce symptoms such as temporary loss of 
vision (amaurosis fugax), transient neurological dysfunction (transient ischemic attack, TIA), 
or stroke. Stroke is an important cause of immediate death or severe disability including the 
need for lifelong care, reflected in the nearly 40 million disability adjusted life years lost to 
ischemic stroke47. 
Amaurosis fugax, TIAs or stroke are indications for carotid endarterectomy (CEA), a surgical 
procedure where the carotid artery is isolated, clamped, and opened to remove the plaque. 
Also eligible for this procedure are asymptomatic patients with a significant carotid 
stenosis48, but in the majority of cases, the perioperative surgical risk of approximately 3% 
still outweighs the risk of plaque rupture49,50. New screening and imaging techniques allow 
for accurate detection of vulnerable plaque22,23. Ways to not only diagnose, but also stabilize 
such a lesion biologically rather than surgically, for example by stimulating the intrinsic 
healing response, would improve patients’ perspectives and help clinicians make treatment 
decisions. 
1.2.3 Radiation vasculopathy 
The increasing efficacy of cancer treatment has led to a growing cohort of cancer survivors51. 
In these ex-patients, long-term adverse effects of cancer treatments are now becoming 
evident52. Radiation-induced vascular disease, or radiation vasculopathy, is an under-
recognized problem in patients previously undergoing radiation therapy (RT) for cancer 
forms in the mediastinal and/or head and neck area (typically breast cancer, Hodgkin’s 
lymphoma, or head and neck squamous cell carcinoma), where the heart and large conduit 
arteries are located53,54. With increasing dosage, local RT increases the risk for ischemic 
heart disease55,56. In patients receiving RT for head and neck squamous cell carcinoma, 
carotid artery irradiation is a significant risk factor for carotid occlusive disease57-59.  
The underlying cause of radiation vasculopathy is radiation-induced arterial inflammation, 
characterized by the expression of inflammatory mediators in the nuclear factor kappa B 
(NF-κB) pathway60. This NF-κB activation is chronic and detrimental, and is not only 
suspected to induce a more aggressive form of atherosclerosis; it also causes thrombosis and 
subsequent failure of non-vascularized transplanted tissue61,62. As the survival rates of cancer 
patients improve, there is a need for novel therapies to halt the vascular inflammatory 
reaction if the goal is to aim for a healthy, rather than merely cancer-free life for cancer 
survivors. 
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1.3 NON-CODING RNA 
The ‘central dogma of molecular biology’, first described by Watson and Crick in 1953, 
states that there is a unidirectional flow of genetic information from the DNA. Via 
transcription of messenger RNA (mRNA), information is translated into proteins, which 
regulate cellular function. That there might be exceptions to this rule, has been proposed less 
than a decade later63, but was not further investigated until the discovery of ‘bacterial 
interfering RNA’ in 198464. Describing this phenomenon for the first time in an animal 
model, Lee et al sparked the interest in the biological functions of RNA interference 
(RNAi)65. Gradually, all the genetic information not directly encoding proteins, previously 
called ‘junk DNA’, is now being mapped and showing that not 1-3%, but actually 
approximately 80%, of our DNA sequence is potentially functional66,67. 
A variety of functional elements (hereafter non-coding RNA, ncRNA) are actively 
transcribed from the human DNA, and interfere with cellular processes at many levels, 
thereby continuously challenging current knowledge about gene function68. Present-day 
literature distinguishes between a multitude of ncRNA subclasses, depending on function, 
size, structure and genomic location68,69. Almost every newly discovered ncRNA has a 
different physiological role, which makes generalization of ncRNA function difficult70,71. 
ncRNAs can be sub-classified according to function, which can be structural (transfer-RNAs, 
ribosomal RNAs, small nucleolar RNAs) or regulatory (microRNAs, piwi-interacting RNAs, 
small interfering RNAs). For ncRNAs with as of yet unknown function, sub-classifications 
can be made based on structure (circular RNAs) and location (long intergenic RNAs, 
enhancer RNAs), but the most common cutoff used is length (larger or smaller than 200 
nucleotides). Interestingly, the number of non-coding transcripts increases exponentially 
with species complexity, where coding transcripts seem to asymptote around 30,00072. 
ncRNAs can therefore be viewed as ‘adapters’, providing specificity to the molecule-to-
molecule communication inside cells: information needed to perform complex biological 
tasks. This implies that ncRNAs can give information about the temporal and developmental 
state of a cell, in an even more specific manner than proteins or mRNAs73. A disadvantage to 
this specificity is that ncRNAs typically are fewer in number and more transiently expressed, 
and therefore less easily detectable. This technological challenge can be overcome to a 
certain extent by deep sequencing techniques such as RNA-sequencing (RNA-Seq), but this 
generates enormous amounts of transcriptomic information74. The extraction of biologically 
meaningful elements, the assessment of their contribution to disease, and the definition of 
their therapeutic potential, requires a combination of bioinformatics, chemistry, cellular 
biology, and medicine. When determining therapeutic interest, an important selection 
criterion for certain ncRNAs, especially miRNAs, is conservation among species75. The 
reasons for this are two-fold: conservation gives an indication of the relevance of ncRNAs, 
and allows for experimentation in vivo. That a ncRNA is not conserved, however, does not 
necessarily indicate its redundancy. This seems to be the case particularly for long noncoding 
RNAs (lncRNAs)76. 
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1.3.1 MicroRNAs 
 MicroRNAs (miRNAs) are 20-to-22-nucleotide-long single-stranded ncRNA molecules that 
are able to base pair with homologous 8-nucleotide-long seed sequences within target 
mRNA molecules. miRNAs generally reside in the cell cytoplasm, coupled to RNA-binding 
protein Argonaute 2 (AGO2). Together with the enzyme Dicer, AGO2 forms the active part 
of the RNA-induced silencing complex (RISC), responsible for RNA-induced silencing or 
RNAi77. RISC activation induces mRNA deadenylation and decay, or other types of post-
transcriptional regulation. The net effect is, typically, repression of protein translation (Fig. 
1.4). Because one miRNA can have multiple mRNA targets, miRNAs are able to influence 
several steps in biological processes, e.g. signaling cascades, 
making them powerful modulators of these processes78. Genomic 
variants affecting miRNA:mRNA pairing can influence miRNA-
mediated gene expression regulation79. Thus, data from genome-
wide association studies can be combined with information about 
miRNA functionality, in order to find miRNAs involved in, for 
example, cardiovascular disease risk80. These discoveries are 
generally made in silico and, therefore, merely explorative. 
Whether the identified variants indeed do confer an altered disease 
risk always needs to be verified experimentally. 
Figure 1.4. miRNAs base pair with mRNA, inducing its de-
adenylation and decay. The net effect is inhibition of protein 
translation. 
 
miRNA nomenclature is based on the order of their discovery. The first known miRNAs, lin-
4 and let-7, are logical exceptions to this rule65. To date more than 28,000 miRNA transcripts 
have been identified81. Typically, miRNAs are annotated starting with the species they can 
be found in (e.g. homo sapiens, hsa; mus musculus, mmu), followed by a number, and a 
suffix -3p (indicating the 3’ strand derived from the stem-loop precursor) or -5p (the 5’ 
strand). Since the ncRNA field is developing rapidly, nomenclature rules are subject to 
change; some publications still refer to the 3’ strand as the ‘star’ (*) strand, based on the 
assumption that this ‘passenger’ strand has less biological meaning than the ‘original’ 
miRNA. As many 3’ miRNAs turned out to have important functions and could by no means 
be considered inferior to their 5’ counterpart, the ‘star’ annotation was abandoned. miRNAs 
differing only in 1 or 2 nucleotides, often with largely the same gene targets, are commonly 
grouped and receive the suffix -a, -b, -c, etc. Most well-studied miRNA sequences are 
conserved among species, and therefore a commonly used approach to explore miRNA 
function is to generate a knockout animal. This approach has the additional advantage that in 
physiological conditions, most miRNAs seem to be redundant. miRNA knockout mice 
generally do not have a striking phenotype, and modulation of miRNAs with artificial 
inhibitors (anti-miRs or antagomiRs) or enhancers (miRNA mimics or pre-miRs) is well 
tolerated under normal conditions in vitro and in vivo. However, when cells or organisms are 
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stressed, e.g. in disease states or during starvation, miRNAs limit the amount of mRNA 
escaping excess transcription. In this way they contribute to stabilizing a cell’s physiological 
state, hence the popular annotation of miRNAs as ‘fine tuners’ of cell output78 and sustainers 
of a bi-stable or oscillatory cellular state82. Dependent on cell type, disease progression, and 
other physiologic parameters, miRNA interference can be beneficial or detrimental, and 
therapeutic interest exists for anti-miRs as well as pre-miRs. 
Apart from their intracellular functions, miRNAs can be detected in the circulation, and are 
hypothesized to take part in information exchange between cells in an organism. Complete 
fields of research are dedicated to determining what type of subcellular carriers are 
responsible for this intercellular communication, and their putative modes of action83,84. It is 
likely that the type of carrier, and the extent to which a specific miRNA is involved in this 
system, is cell-specific. By using qRT-PCR, deregulated levels of miRNAs can be 
reproducibly detected and quantified85. miRNAs measured in the circulation have been 
shown to contribute to estimating the risk of cancer86 myocardial infarction87, and AAA 
progression88. There are, however, caveats to this approach. Medication can be an important 
confounding factor when measuring levels of circulating miRNAs, as certain drugs are 
known to hamper the expression of some cell-specific miRNAs85. Awareness of and 
correction for confounders, as well as uniform sampling and sample processing, are therefore 
imperative in miRNA research. 
1.3.2 Therapeutic applications of non-coding RNAs 
Besides their diagnostic function, perturbations in ncRNA expression can be altered with 
specific modulators, in order to change the disease course. An example of successful ncRNA 
therapy is blockage of miR-122, which in patients with hepatitis C virus can reduce viral 
titers to undetectable89. Despite the potential of RNAi therapy, there is a discrepancy 
between the number of ncRNAs shown to be of therapeutic interest based on in silico and in 
vitro studies, and those being investigated as therapeutic targets in vivo. With the exception 
of organs and tissues amenable for topical therapy – the eye, skin, and local tumors – it is 
technically difficult to direct ncRNA-modifying drugs to a target organ, or cell, without 
affecting other cells. The currently most widely used approach to envelope and deliver 
ncRNA modulators is with nanoparticles and liposomal carriers. In this context, it is not 
surprising that liver disease emerged as the first successful therapeutic application of anti-
miRs89 given the affinity of hepatocytes for particles with liposomal size and structure90. 
Several other chemical compounds have been investigated as candidate vehicles91 in this 
rapidly developing field. 
Therapeutic modulation of miRNA function involves inhibition as well as stimulation. 
Inhibition of miRNAs generally means inactivation, and because of the fact that miRNAs 
operate in the cytoplasm, anti-miRs need only be delivered to the cellular periphery. By 
constructing oligonucleotides with an artificially added bonding bridge in the ribose moiety 
of the nucleotide, it is possible to create a molecule able to irreversibly bind to miRNA. This 
‘locked nucleic acid’ (LNA) technique produces a double-stranded RNA molecule, which is 
degraded by the cell. The most successful example of LNA-mediated miRNA inhibition is 
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the aforementioned miR-122-antagonizing therapy, applied in hepatitis C virus patients. 
Since miR-122 is essential for the virus to replicate, anti-miR-122 rendered patients virus-
free89. Introducing miRNA mimics is more challenging, because a cell needs to process the 
mimic construct such that it is incorporated in the RISC. This requires introduction into the 
nucleus, and to achieve this, more advanced chemical modifications are needed. 
For administration of nucleic acid-modifying therapies in vivo, including miRNA mimics, 
the most clinically advanced techniques are virus-based. Adenovirus92, adeno-associated 
virus93, and retroviruses94 are approved by regulatory agencies and used in clinical trials. We 
successfully used a lentiviral vector to administer pre- and anti-miR-24 in mouse AAA 
development (Paper I). Viral vectors are an effective, yet controversial, delivery method. A 
primary concern is the propensity of adenoviral particles to trigger an immunogenic 
response, thereby causing adverse symptoms or inactivating their therapeutic effects. 
Immunosuppressive therapy can dampen this unwanted immunogenicity, but may expose a 
patient to opportunistic infectious diseases. For retroviral vectors, integration of the viral 
genetic material into the host DNA is a major issue. Retroviruses tend to integrate genetic 
material into promoter regions. This has shown to be deleterious in a clinical trial, where 
pediatric patients, treated for immunodeficiency, developed leukemia95. Other issues such as 
vector mobility, where virus particles travel beyond the area of interest, and high production 
costs, have initiated a search for non-viral strategies96. 
An efficient, commercially available non-viral vector is polyethyleneimine (PEI). PEI is a 
strongly cationic polymer, which can be used to package nucleic acids into positively 
charged particles. When presented to the negatively charged cell surface, PEI particles 
undergo endocytosis and, once in the cytosol, render the nucleic acid free to enter the 
nucleus97. PEI-delivered miRNA mimics injected systemically reach a variety of organs98, 
including blood vessels99, without eliciting a major immune response. We successfully used 
PEI to deliver mimics of miR-210 and miR-29b to murine SMCs in carotid plaque (Paper 
III) and radiation vasculopathy (Paper IV). 
There are disadvantages to the use of PEI, for example its direct cytotoxicity100,101. For 
ncRNA-modulating technologies in general, the aim is to minimalize complications such as 
unwanted reactions, side effects, hypersensitivity, inadequate concentration at target 
locations and potentially rapid clearance of the therapeutic substance. Non-systemic, i.e. 
local, administration techniques are gaining interest96. In vascular disease, drug-eluting stents 
have emerged as potential ncRNA carriers: In a humanized rat model, an anti-miR-21 eluting 
stent increased the local availability of the miRNA modulator whilst avoiding toxicity in 
other organs, which indeed was a problem with systemic treatment102. More revolutionary 
delivery techniques include drug-containing microbubbles burst by ultrasound waves103 or 
‘sonoporation’ (ultrasound-triggered opening of membrane pores) to deliver e.g. PEI104. 
Whether these techniques will finally reach the clinic, depends largely on their efficacy in 
(pre)clinical studies. An important translational step is the transition from mice to larger 
animal models such as pigs, which have a greater similarity to humans both in size and 
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taxonomy105 and can be genetically modified to develop cardiovascular disease106. Our group 
is at the forefront of these developments. 
1.4 NON-CODING RNAS IN CARDIOVASCULAR DISEASE 
The cardiovascular system is a strictly regulated network sensitive to small perturbations. 
The functional characteristics of ncRNAs as regulators of cell fate make them particularly 
suited to control vascular development and homeostasis in physiological conditions. Their 
role in cardiovascular disease has also been well established107. 
1.4.1 Non-coding RNAs in vascular smooth muscle cell biology 
Perhaps one of the best-described miRNAs inducing a proliferative vascular smooth muscle 
cell phenotype is miR-21. In cancer, miR-21 is characterized as ‘onco-miR’, promoting 
cancer cell proliferation and metastasis. Among miR-21 targets are the tumor suppressor 
genes B-cell CLL/lymphoma 2 (BCL2), phosphatase and tensin homolog (PTEN) and 
programmed cell death protein 4 (PDCD4). In vascular smooth muscle cells, miR-21 induces 
a dedifferentiated, proliferative phenotype, which contributes to e.g. in-stent restenosis in 
percutaneous coronary interventions (PCI). Anti-miR-21 therapy was able to prevent SMC 
proliferation and reduce in-stent restenosis102. That SMC dedifferentiation is not necessarily 
detrimental was shown in animal models of AAA. miR-21 overexpression prevented AAA 
rupture and expansion, due to a proliferative, anti-apoptotic effect via inhibition of PTEN in 
SMCs108. In atherosclerotic plaque development, miR-21 could also have stabilizing effects 
by increasing the number of SMCs in the fibrous cap. 
The miR-143/145 cluster is highly expressed in SMCs and was one of the first miRNA 
groups shown to induce SMC contractility and counteract pathological changes by targeting 
KLF4 mRNA109. Besides KLF4, miR-143/145 target an array of proliferative factors 
including platelet-derived growth factor (PDGF) and angiotensin-converting enzyme (ACE). 
In AAA and atherosclerosis, dedifferentiated vascular smooth muscle cells can contribute to 
stabilizing the vessel wall by producing extracellular matrix. The miR-29 family consists of 
three members, miR-29a, -b and -c. Together, these miRNAs target at least 16 genes related 
to extracellular matrix production110. Higher expression of miR-29 is associated with 
aneurysm expansion in humans and mice, and inhibition of miR-29 family members 
effectively prevents aneurysm expansion in mice111,112 and affects vascular wall strength and 
elasticity113. In tissues such as the lungs114 and heart115, miR-29b regulates fibrosis. Indeed, 
when expanding the view on fibrotic diseases, and including other organs such as the kidney, 
a broad interest in ncRNA involvement can be seen. Two lncRNAs, np_5318 and np_17856, 
have been functionally linked to progressive kidney injury116. Under hyperglycemic 
conditions, kidney cells upregulate expression of miR-1207-5p and its host gene, lncRNA 
plasmacytoma variant translocation 1 (PVT1)117. Because all of these ncRNAs operate 
through the same fibrosis-related cellular mechanistic pathways, like miR-29, it is likely that 
they also have an impact on vascular disease. 
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PDGF release stimulates expression of the cluster miR-221/222, promoting a proliferative 
phenotype in SMCs via targeting of the cell-cycle inhibitors cyclin-dependent kinase 
inhibitor 1B (CDKN1B) and –1C (CDKN1C). The stem cell factor KIT, responsible for 
myocardin transcription, also belongs to the miR-221/222 targets30, further strengthening the 
SMC dedifferentiating function of these miRNAs. Angiotensin II (ANGII), mediator of 
hypertension and a well-known culprit factor in cardiovascular disease, induces expression 
of several lncRNAs. In rat cells, one of these ANGII-responsive lncRNAs, Lnc-Ang362 or 
MIR222HG, is a host gene for miR-221/222, meaning that the lncRNA and miRNA cluster 
are co-transcribed in these cells118. This example illustrates how tightly interwoven the 
network of ncRNA regulation can be. 
RNA-Seq studies in human vascular cells uncovered Smooth muscle and Endothelial cel-
enriched migration/differentiation-associated long Non-Coding RNA (SENCR) as a lncRNA 
involved in the contractile gene program of SMCs. Knockdown of this lncRNA showed an 
increase in SMC motility and loss of contractile proteins, suggesting a role for SENCR in the 
maintenance of a ‘normal’, differentiated SMC phenotype119. 
H19 is a maternally imprinted gene mostly expressed during embryonic development120. 
Most studies suggest a growth-promoting effect of H19, for example in skeletal muscle121 
and myogenic progenitor cells122, but also cancer cells123,124. After vascular injury, 
phenotypic changes of SMCs have been associated with increased expression of H19 in rats, 
possibly displaying a role of H19 in neointima formation125.  
 
Figure 1.5. SMCs respond to pathologic stimuli by dedifferentiation, characterized by 
proliferation and extracellular matrix production. ncRNAs affect this process through many 
biological pathways. 
1.4.2 Non-coding RNA in vascular endothelial cell biology 
Through its demonstrated effects on vascular endothelial cells (ECs), miR-126 is well 
known as a regulator of vascular integrity, both during embryonic development126 and in 
atherosclerosis127. Circulating miR-126 expression has been associated with a reduced 
cardiovascular risk, which suggests an important role for microvesicles as miRNA 
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carriers128. In a carotid re-endothelialization model, nanoparticle-mediated delivery of pro-
angiogenic miR-126 improved endothelial repair129. miR-126 has also shown to be abundant 
in platelets, a finding that challenged the endothelial origin in the context of changes in 
circulating miR-126 levels, and which also suggested antiplatelet treatment as a confounder 
for deregulated miR-126 levels. This stresses the importance of a proper patient control 
selection and the use of a co-expression network of miRNAs, rather than one miRNA, when 
exploring the diagnostic potential of miRNAs. 
Other miRNAs associated with EC (patho-)physiology are the miR-17≈92a cluster and 
miR-23≈27≈24. Members of the miR-17≈92a cluster include miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b-1 and miR-92-1, and target EC functions such as angiogenesis, sprouting 
and vascular remodeling via sirtuin 1 (SIRT1), integrin subunit alpha 5 (ITGA5), Janus 
kinase 1 (JAK1), sprouty protein 2 (SPROUTY2), and semaphorin-6A (SEMA6A)130-132. 
‘Myocardial infarction-associated transcript’, MIAT, is an example of a long non-coding 
RNA whose expression is correlated with cardiovascular risk. At approximately 9 kilobases, 
the transcript is substantially larger than a miRNA, but does not encode any translational 
product. Overexpression- and inhibition studies in vitro and in vivo have thus far shown 
effects of MIAT in a range of cell types and disease conditions, from schizophrenia to 
diabetic retinopathy133. The latter association of MIAT with microvascular dysfunction was 
attributed to competing effects of MIAT and miR-150-5p on VEGF, with MIAT functioning 
as a miRNA sponge alleviating the miR-150-5p inhibition on VEGF134. Unpublished work 
from our group suggests a key role for MIAT not only in endothelial cells, but also for 
smooth muscle cells during atherosclerotic plaque stabilization processes (Li et al, 
unpublished). 
A long non-coding RNA with a more clearly elucidated function in endothelial dysfunction 
and diabetes is ‘metastasis associated lung adenocarcinoma transcript’ MALAT1. MALAT1 
is highly conserved among mammals, is localized in the nucleus and controls functional 
levels of serine/arginine splicing factors, thereby regulating alternative splicing135. In 
endothelial cells, MALAT1 is induced upon hypoxic stress, and its effects are pro-
proliferative and anti-apoptotic136. Because of its effects on endothelial cells, a role in 
diabetic nephropathy and overall endothelial function has been attributed to MALAT1137. 
In human endothelial cells subjected to hypoxia, two long intergenic RNAs (LINC00323 
and MIR503HG) are induced and have been linked to angiogenic capacity. Modulation of 
these ncRNAs could have impact on tissue vascularization and recovery after ischemia138. 
1.4.3 Non-coding RNA in vascular inflammation 
In autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and systemic lupus 
erythematosus, miR-155 is induced. An increase miR-155 expression was found to be 
downstream of pro-inflammatory stimuli such as tumor necrosis factor (TNF), Toll-like 
receptors (TLRs), and NF-κB signaling and it has been demonstrated to be involved in 
regulation of B and T cell responses, as well as innate immunity139. Inhibition of miR-155 
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has been shown to dampen rheumatoid arthritis in mice140. In a cardiovascular context, miR-
155 has been studied extensively with regard to its role in inflammation, sustaining and 
aggravating atherosclerosis, indicating atheroprotective141 as well as detrimental142 effects of 
this miRNA. 
The two members of the miR-146 family, miR-146a and miR-146b, are induced by 
inflammatory components of the NF-κB pathway143. Both miRNAs have an identical seed 
sequence, which targets the 3’ UTR of many genes in the same pathway, such as interleukin 
1 receptor associated kinase 1 (IRAK1), nuclear factor kappa B subunit 1 (NFKB1), Toll-
like receptor 4 (TLR4), and TNF receptor associated factor 6 (TRAF6)144. Enforced miR-
146b expression in monocytes leads to a reduction in at least seven inflammatory 
cytokines145,146, supporting the notion that these miRNAs might be part of a feedback loop 
limiting inflammation. In human atherosclerotic plaque, miR-146a and -b are upregulated147, 
and miR-146b-5p is known to promote platelet-derived growth factor-BB (PDGF-BB)-
induced SMC proliferation and migration148, which ay contribute to a stable plaque 
phenotype. 
miR-150 is a key regulator of immune cell differentiation and activation149,150. In patients 
with critical illness and sepsis, its expression is predictive for survival151. miR-181 is 
expressed in vascular- as well as immune cells, and is critically involved in vascular 
inflammation through its effects on the NF-κB signaling pathway152. Human monocytes 
stimulated with the immune response-trigger lipopolysacchararide (LPS) upregulate the 
ncRNAs IL1β-eRNA and IL1β-RBT46(+), both containing significant enrichment for NF-
κB binding sites153. 
1.5 BIOMARKERS 
By providing information about ongoing cellular processes, biomarkers can help to diagnose 
and manage cardiovascular disease. A biomarker is a compound released by cells or tissues, 
and which can be detected in order to give information about the presence and progression of 
disease, as well as determine which treatment will most likely benefit the patient (Fig. 1.6). 
An ideal biomarker can be found non-invasively (e.g. in blood plasma, urine, or saliva), is 
sensitive and specific, has a fast and cheap detection method, and detects a treatable 
condition154. 
Figure 1.6. 
Biomarkers can 
indicate which 
patient will most 
likely benefit 
from which 
treatment. 
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ncRNAs, especially miRNAs, are attractive disease biomarkers. Whereas ‘naked’ RNA is 
rapidly degraded in the circulation, miRNAs can be stable in peripheral blood, but also under 
unfavorable handling conditions such as room temperature– and repeated freeze-thaw 
cycles155. There are even reports that propose a role for miRNA in forensics156 because of 
their stability in stored specimens. The stability of miRNAs is often attributed to their 
folding, as well as the tendency of cells to release these molecules in subcellular envelopes 
such as microvesicles, exosomes and apoptotic bodies, which provide a barrier against 
degradation. Other subcellular carriers of miRNAs reported are HDL molecules and proteins 
such as argonaute II (AGO2)84. There even are reports that miRNA-carrying vesicles 
released by cells can be taken up by recipient cells in a paracrine manner, or even by distant 
organs, indicating that this vesicular miRNA transport is targeted, rather than random157. 
Many questions remain to be answered in extracellular vesicle research, which on its own 
encompasses an entire expanding research field83. 
Another advantage of miRNAs as biomarkers is their sensitivity and specificity158, given that 
certain miRNAs are tissue-specific (e.g. miR-208 for myocytes), and so-called ‘co-
expression networks’, indicating a panel of deregulated miRNAs representing a disease 
phenotype, can provide a detailed ‘signature’ of a disease and its progression. They can 
easily be quantified by quantitative reverse transcriptase-polymerase chain reaction (qRT-
PCR). 
A more recently discovered class of ncRNAs, circular RNA (circRNA), possesses intrinsic 
stability. circRNAs are ncRNAs joined at their 3’-5’ ends by a process named ‘backsplicing’, 
thus lacking sequence ‘exposed’ to endonucleases, a structural feature rendering them 
exceptionally stable159. Unraveling of the function of circRNA has caught on in many 
research fields, with some reports showing that they can serve as ‘sponges’ for miRNAs, 
thereby suppressing miRNA activity160. Future studies might lead to the conclusion that the 
biomarker potential of circRNAs, due to their stability and cell specificity, equals – if not 
exceeds – that of miRNAs as well as other ncRNA species. 
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2 THE PRESENT STUDY 
2.1 AIMS 
The general aims of this thesis are to define which non-coding RNAs play a role in vascular 
remodeling and atherosclerotic plaque formation, and how modification of non-coding RNAs 
can contribute to inhibiting these pathologic processes. 
The specific aims per paper are as follows: 
Paper I To find miRNAs associated with murine and human AAA development and 
progression, and to investigate whether modification of these miRNAs can mitigate AAA. 
Paper II To identify miRNAs that can be used as plasma biomarker for AAA 
development and rupture. 
Paper III To investigate miRNAs of clinical interest in patients with carotid stenosis at 
risk of stroke, and to see if modulation of these miRNAs can prevent carotid plaque rupture. 
Paper IV To investigate which vascular disease-related miRNAs are affected in radiation-
induced vasculopathy, and if modification of these miRNAs can dampen the vascular 
inflammatory reaction. 
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2.2 METHODS 
This section includes a summary of methods used in the various projects. Detailed method 
descriptions can be found in the respective manuscripts. 
2.2.1 Human biobank material 
All Swedish studies were approved by the Ethical Committee of Northern Stockholm. 
SMART was approved by the University Hospital Utrecht ethics committee. For all studies, 
patient informed consent was obtained according to the Declaration of Helsinki. 
2.2.2 Abdominal aortic aneurysm disease 
2.2.2.1 FAD 
Patients referred from 2006-2014 to the Department for Vascular Surgery of the Karolinska 
University Hospital for open or endovascular repair of an AAA were included in the study. 
The study was supported by EU grants under the 7th Framework Programme Fighting 
Aneurysm Disease (FAD, project ID 200674). Control blood plasma donors were recruited 
from patients referred to the Vascular Surgery department for non-AAA atherosclerosis-
related symptoms. Informed consent was obtained from all patients. Blood was sampled 
during preoperative consultation and processed according to standard procedures for 
separation of the mononuclear cell fraction and RNA isolation. During open AAA repair 
surgery, biopsies of the aortic wall were sampled, and stored at -80°C until RNA isolation. 
2.2.2.2 SMART 
Rationale and design of the SMART study cohort, as well as abdominal aortic aneurysm 
(AAA) definition and policy, have been described in detail before161,162. Briefly, patients aged 
18-80 with clinically manifest vascular disease or cardiovascular risk factors, referred to the 
University Medical Center Utrecht, The Netherlands, were enrolled. Patients received a 
standardized vascular screening including a health questionnaire, laboratory assessment, and 
ultrasonography. For this study, we included 200 SMART patients with ultrasonographically 
defined AAA, i.e. aortic diameter >30 mm, and 200 age-, gender-, CVD risk profile- and 
medication-matched non-AAA SMART control patients. Follow-up ultrasound examinations 
were conducted annually for AAAs between 30-39 mm; AAAs 40-55 mm were followed up 
biannually. AAAs >55 mm were considered an indication for surgical repair. The treatment 
policy was a recommendation; final treatment decision was subsequently made between 
treating specialists and patients. From patients who were eligible for AAA repair, additional 
blood was sampled 6 months after surgery. 
2.2.3 Carotid atherosclerotic disease: BiKE 
Patients undergoing surgery for symptomatic or asymptomatic high-grade (>50% NASCET) 
carotid stenosis at the Department for Vascular Surgery, Karolinska University Hospital, 
were consecutively enrolled in the Biobank of Karolinska Endarterectomies (BiKE) and 
clinical data recorded on admission. The BiKE study cohort demographics, details of sample 
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processing including control (normal artery) samples have been previously described163. 
Briefly, symptoms of plaque instability were defined as transient ischemic attack (TIA), 
minor stroke or amaurosis fugax. Patients without qualifying symptoms within six months 
prior to surgery were categorized as asymptomatic and indication for carotid endarterectomy 
(CEA) based on results from the Asymptomatic Carotid Surgery Trial (ACST)49. Patients 
with known atrial fibrillation were excluded. For this study, carotid endarterectomy tissue and 
blood samples from n=7 symptomatic and n=5 asymptomatic subjects were collected during 
surgery. We validated our findings in local plasma samples in a separate BiKE validation 
cohort of 7 versus 7 patients. During clamping of the carotid artery for 5 minutes before 
opening of the vessel, blood from the lesion site was sampled in EDTA-containing tubes. The 
resultant plasma samples were stored at -80°C before further processing. Hemolytic plasma 
samples were excluded from miRNA analysis. All studies were approved by the Ethical 
Committee of Northern Stockholm; patient informed consent was obtained according to the 
Declaration of Helsinki. 
2.2.4 Radiation vasculopathy 
We have analyzed samples from Karolinska University Hospital’s Biobank of Irradiated 
Tissues at Karolinska (BIRKA). 15 pairs of arterial biopsies were harvested during head and 
neck cancer reconstruction with microvascular free tissue transfer in 15 preoperatively 
radiated patients. Before performing microvascular anastomosis, biopsies were harvested 
from the radiated cervical artery (recipient site) and from the non-radiated (donor) artery of 
the transferred autologous tissue. Biopsies were dissected from surrounding tissue and 
surgical material under a dissection microscope, where care was taken not to damage the 
endothelium. Vascular tissue was frozen and stored at -80°C until RNA extraction. For 
immunohistochemical analysis, tissue from a paired subset of three patients was fixed in 10% 
formalin and paraffin-embedded. 
2.2.5 Murine models 
The use of mice as a model to study atherosclerosis has advantages as well as disadvantages. 
Their relatively low cost, small size, and the availability of well-characterized, inbred strains 
make them a popular animal model. Disadvantages are the immunological differences 
between mouse and human164, and genetic dissimilarity165. Porcine models are a logical next 
step in the translation of basic vascular biological principles and treatment options into 
clinical applications. In ncRNA research, this step has been taken for in-stent restenosis166 
and ischemia/reperfusion injury167, and our current efforts include a miRNA profile of 
porcine aneurysm expansion (unpublished). 
The by far most important disadvantage of mouse- as well as pig models in cardiovascular 
research is their complete (mice) or advanced (pigs) resistance to atherosclerosis. For 
cardiovascular research, investigators resort to genetically modified, high-cholesterol 
animals, such as low-density lipoprotein receptor- (Ldlr-/-), and apolipoprotein E (Apoe-/-) 
knockout mice, and LDLR-/- pigs106. Alternatively, or in combination with genetic knockout, 
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surgical and chemical manipulation and diet-induced metabolic disruption are methods we 
used to generate cardiovascular disease phenotypes. 
2.2.5.1 Angiotensin II infusion 
As a model of AAA formation and rupture, we used angiotensin II (ANGII) infusion in male 
Apoe-/- mice, first described by Daugherty et al168. Briefly, osmotic minipumps releasing 
ANGII at 1,000 ng/kg min-1 were placed under 2% isoflurane anesthesia. This ANGII dosage 
is reported to increase blood pressure by approximately 25 mmHg. In this model, AAA 
formation however does not seem to be caused by hypertension, since dampening as well as 
complete prevention of AAA formation has been achieved without blood pressure 
lowering108,169. At the pathological basis of AAA formation in this model is the mass influx 
of macrophages to the vascular medial layer and associated elastin degradation170. Using 
ultrasound (Vevo 2100, Visualsonics, Toronto, Canada), we measured the maximum 
infrarenal aortic diameter at baseline and at 7, 14, and 28 days after pump implantation. On 
day 7, blood was sampled in EDTA containers and centrifuged at 10,000×G for 10 minutes. 
On day 28, mice were sacrificed through CO2 inhalation, exsanguinated by heart puncture, 
and perfused with 4°C PBS before organ harvesting. Aortas were embedded in OCT 
compound (Histolab, Gothenburg, Sweden), or snap-frozen, and stored at -80°C. 
2.2.5.2 Isolating peritoneal mouse macrophages 
Mice were euthanized by CO2, 4 days after injection of Brewer’s thioglycollate (Sigma-
Aldrich, St. Louis, MO, USA). A quantity of 5 mL of 4°C phosphate-buffered saline (PBS) 
was injected twice into the peritoneal cavity of Apoe-/- mice with or without ANGII-induced 
AAA. Macrophages were then withdrawn from the intraperitoneal cavity and put into 
suspension, centrifuged at 1,500 rpm for 5 min at 4°C and 5 mL of RBC lysis buffer was 
added to the pellet. After incubation and centrifugation, 1 mL of 37°C RPMI 1640, 10% fetal 
bovine serum (FBS) and 1% penicillin/streptomycin (PEST, all Gibco, Thermo Fisher 
Scientific) per mouse were added to the pellet. After counting and dilution (10-fold), cells 
were plated, analyzed, and used for further experiments. 
2.2.5.3 Porcine pancreatic elastase infusion 
The porcine pancreatic elastase infusion model (PPE) as an in vivo approach to infrarenal 
aneurysm formation was first described in rats by Anidjar et al171 and adapted for mice by 
Pyo et al172. We used a modified version of the mouse PPE model as visually presented by 
Azuma et al173. Briefly, male C57/BL6 mice (Charles River, Wilmington, MA, USA) were 
anesthetized with 2% isoflurane. The abdominal cavity was accessed through median 
laparotomy and the retroperitoneum exposed with retractors, leaving the intestines in situ. 
After opening of the retroperitoneum, the aorta and inferior vena cava were separated from 
the level of the left renal vein to the aortic bifurcation. All aortic branches within 1 cm of the 
bifurcation were temporarily ligated with 6.0 silk ligatures (Vömel, Kronberg, Germany). 
After placement of proximal and distal temporary silk sutures, aortotomy was performed with 
the tip of a 30-gauge needle. Through the aortotomy, a heat-tapered PE-10 polyethene 
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catheter was introduced and secured with a silk ligature. The isolated aortic segment was 
infused with PPE solution (1.5 U/mL in PBS; Worthington Biochemical Corporation, 
Lakewood, NJ, USA) under sufficient pressure to achieve a 50-70% aortic expansion for the 
duration of 8 minutes; control mice received PBS. After removal of the catheter, the aortic 
segment was flushed with saline and the aortotomy closed with a 10.0 polyamide 
monofilament suture (B Braun, Melsungen, Germany). Temporary ligations were removed 
and the abdominal wall closed with 5.0 Vicryl sutures (Ethicon, Somerville, NJ, USA), 
followed by closure of the skin. Mice received 0.1 mg/kg buprenorphine as post-operative 
analgesic. At 7, 14 and 28 days after PPE infusion, aortic aneurysm size was assessed by 
ultrasound (Vevo 2100, Visualsonics, Toronto, Canada), measuring maximum infrarenal 
aortic diameter. Four weeks after surgery, animals were sacrificed with CO2 inhalation, 
exsanguinated by heart puncture, and perfused with 4°C PBS before organ harvesting. Aortas 
were embedded in OCT compound (Histolab, Gothenburg, Sweden), or snap-frozen, and 
stored at -80°C. 
2.2.5.4 Carotid ligation – cast 
Male, 12-week old Apoe-/- mice (Taconic, Hudson, NY, USA) were used for this experiment. 
Ad libitum access to water and food (standard chow diet) was ensured. Animals were 
anesthetized with 2.0% isoflurane-containing oxygenated air for the duration of surgical 
procedures. Depth of anesthesia was verified by toe pinching. Via medial neck incision, the 
right carotid artery was separated from the surrounding connective tissue. A 5.0 Vicryl suture 
(Ethicon, Somerville, NJ, USA) was placed around the common carotid artery, directly below 
the carotid bifurcation. The skin was closed with 5.0 Vicryl sutures (Ethicon). Twenty-eight 
days after ligation, a plastic 1.7 mm long cast consisting of two rigid halves (Promolding BV, 
Rijswijk, Netherlands) with a cone-shaped internal lumen ranging from 150 µm (distal) to 
300 µm (proximal), was placed around the common carotid artery, directly proximal to the 
ligation (Fig. 2.1). Before cast placement, presence of flow through the ligated part of the 
common carotid artery was verified with Doppler-enhanced ultrasound (Vevo 2100, 
Visualsonics, Toronto, Canada). Four days after cast placement, animals were sacrificed 
through CO2 inhalation, exsanguinated by heart puncture and perfused with 4°C PBS. Organs 
were snap frozen in dry ice-containing ethanol and stored at -80 °C. The left carotid artery 
was embedded in Optimal Cutting Temperature (OCT) Cryomount compound (Histolab, 
Gothenburg, Sweden), snap frozen and stored at -80°C. 
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Fig. 2.1 Carotid ligation and cast placement produces plaque formation and rupture in 
≈60% of mice. 
2.2.5.5 Mediastinal irradiation 
For in vivo radiation, we used 10-week-old C57BL6/N Apoe-/- mice (Taconic, Hudson, NY, 
USA) weighing 20-30 grams. Anesthesia consisted of intraperitoneal (i.p) injection of 15 µl 
(50 mg/ml) ketamine (Ketalar, Pfizer, Sollentuna, Sweden), 10 µl (1 mg/ml) of medetomidine 
(Domitor, Orion Pharma Animal Heath, Sollentuna, Sweden) and 75 µl of phosphate buffered 
saline (PBS). Depth of anesthesia was verified with a pedal reflex test. Animals were fixated 
onto a heating pad and covered by a 7 mm thick lead chamber with an open area (1.5 × 2.2 
cm) also restricted by a collimator (2.5 × 2 cm) exposing the upper chest and neck region to 
radiation beams. Mice were placed in a biological irradiator (X-RAD 320, Precision X-Ray, 
North Branford, USA) and the uncovered area irradiated at 0.7 Gy/min to a total dose of 14 
Gy. Control mice received sham irradiation. After irradiation, mice received atipamezole 
(Antisedan, Orion Pharma Animal Heath, Sollentuna, Sweden) 20 µl (5mg/ml) for anesthesia 
reversal. During the observation period (3 days, 14 days, or 10 weeks), mice received water 
and food ad libitum. Mice were sacrificed through CO2 inhalation; plasma and organs were 
processed as described above. 
2.2.5.6 In vivo miRNA modulation 
To modulate miRNA expression in mice, animals were injected peritoneally with anti-miRs 
(LNA-coupled, Exiqon, Vedbaek, Denmark), miRNA mimics (miRVana, Thermo Fisher 
Scientific), or scrambled control oligonucleotides. Since LNA technology is an effective way 
to trap and degrade miRNAs in the circulation, no additional vectors are needed. Because 
miRNA mimics need to be processed by the cell like pri-miRNA transcripts, transfection is 
more challenging and requires specific chemical packaging. We used Jet-PEI (Polyplus-
transfection, Illkirch-Graffenstaden, France) as vector to ensure nuclear delivery. For both 
groups (Jet-PEI and LNA) we used similarly delivered scrambled control oligonucleotides. 
LNA and mimic dosage were determined based on the manufacturer’s recommendations and 
varied throughout the experiments. 
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2.2.6 Cell culture experiments 
Throughout all experiments, cells were kept at 37°C in an incubator containing atmospheric 
oxygen levels and 5% CO2. For cell detachment, we used 0.05% trypsin-EDTA (Thermo 
Fisher Scientific). All experiments were repeated three times. For protein analysis, cells were 
washed with cold (4°C) PBS, lysed with RIPA buffer cocktail (Sigma-Aldrich) containing 
RIPA buffer, phosphatase- and protease inhibitors, EDTA and sodium azide. The lysate was 
centrifuged at 14,000 rpm for 15 minutes and protein concentration in the resultant 
supernatant measured with a bicinchoninic acid assay (Thermo Fisher Scientific). Protein 
samples were stored at -20°C until analysis. For RNA analysis, cells were washed with warm 
(37°C) PBS, lysed with QIAzol (QIAgen, Hilden, Germany), and RNA extracted with the 
QIAgen miRNeasy Mini or Micro Kit (QIAgen) according to the manufacturer’s instructions, 
using the QIAcube RNA preparation robot (QIAgen). 
2.2.6.1 Cell types 
Primary human carotid artery smooth muscle cells (HCtASMCs), carotid artery endothelial 
cells (HCtAECs) and aortic smooth muscle cells (HAoSMCs) were purchased from Cell 
Applications (San Diego, CA, USA). All three cell types were cultured in complete growth 
medium (Cell Applications). For in vitro experiments, passages 5-9 were used. 
HEK293 cells were purchased from Public Health England Culture Collections, Salisbury, 
UK). Cells were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 
10% FBS and 1% PEST. 
Mouse aortic smooth muscle cells (MAoSMCs) were purchased from ATCC (Manassas, VA, 
USA) and cultured in DMEM supplemented with 10% FBS and 0.2 mg/mL gentamycin (all 
Gibco). 
2.2.6.2 In vitro miRNA modulation 
Cells were seeded at 125,000 cells/well (6-well plate), 60,000 cells/well (12-well plate), 
20,000 cells/well (24-well plate) or 5,000 cells/well (96-well plate). After overnight 
incubation, growth medium was replaced with Opti-MEM (Gibco, Thermo Fisher Scientific) 
serum-free medium supplemented with 0.4% FBS (Gibco). Anti-miRNAs, pre-miRNAs, 
miRNA mimics, or scrambled (negative control) oligonucleotides (all from Ambion, Thermo 
Fisher Scientific), were combined with Lipofectamine RNAiMAX (Invitrogen, Thermo 
Fisher Scientific), diluted in Opti-MEM and applied at 75 nM. 
2.2.6.3 In vitro shear stress 
HCtASMCs or HCtAECs were seeded on untreated glass microscopy slides (Flexcell 
International Corporation, Burlington, VT, USA). ECs were cultured in endothelial cell 
medium (Cell Applications) and seeded on gelatin-coated slides (Flexcell). The cells were 
seeded at a density of 750,000 cells per slide (passage 8-9) and were sub-cultured for 48 
hours to allow firm cell attachment. Streamer medium consisted of high-glucose DMEM 
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(Gibco, Thermo Fisher Scientific) supplemented with 1% L-glutamine, 1% PEST and 5% 
FBS. The shear stress regime included a conditioning phase of 4, 6 and 10 dyn/cm2 (10 
minutes each) followed by 19,5 hours of 12 dyn/cm2. Total shear stress exposure time was 20 
hours. Cells were subjected to either oscillatory or laminar shear stress. Control cells were 
incubated overnight in the same medium (‘static’). 
2.2.6.4 Luciferase reporter assay 
To test miRNA-mediated, posttranscriptional regulation of target genes, a luciferase reporter 
assay was used. Firefly luciferase gene constructs containing the miRNA sequence predicted 
to target the mRNA (the ‘seed’) were purchased from Switchgear Genomics (Active Motif, 
Carlsbad, CA, USA). As control, two mutated seed sequence constructs were used. In brief, 
HEK293 cells or HCtASMCs were seeded on 24-well plates (1×105 cells/well). At 50-60% 
confluence, cells were transfected with luciferase reporter plasmid pLS, pLS-target gene-
3’UTR or its mutant (100 ng/well, Active Motif), together with control or pre-miRNA (10 
nM final concentration) using Dharmafect Duo Transfection Reagent (GE Dharmacon, 
Lafayette, CO, USA) according to the manufacturer’s protocol. After a 24-hour transfection 
period, luciferase activity was quantified using the LightSwitch Luciferase Assay Kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. 
2.2.6.5 Radiation 
HCtASMCs or HCtAECs were plated and cultured overnight before being placed inside a 
biological irradiator. Cells received 2 doses of 2 Gy (0.4 Gy/min; total irradiation time 2×5 
min) with 24 hours between doses. Control cells were taken out of the incubator, but did not 
receive irradiation. Cells were harvested 3, 6, or 24 hours after the last radiation exposure, or 
directly placed in a live-cell imaging incubator (IncuCyte, Essen Bioscience, Hertfordshire, 
UK) and images taken every 2 hours for the course of 5 days. Proliferation was defined as 
increase in cell confluence as average of 16 pictures per well in a 6-well plate. For apoptosis 
measurements, cell medium was supplied with caspase3/7 reagent (Essen Bioscience) at a 
concentration of 5 µM, as recommended by the manufacturer. Apoptosis was measured as 
number of positive cells per photographed area. 
2.2.7 RNA isolation and qRT-PCR analysis 
Cells were washed three times with warm PBS, lysed with 700 µL QIAzol, and scraped off 
with a cell scraper. Homogenization was achieved by pipetting up and down three times. 
Tissues were lysed using a tissue homogenizer (ProScientific, Oxford, MS, USA). RNA 
extraction was performed using the miRNeasy Mini or Micro kit (depending on sample size, 
QIAgen) following the manufacturer’s protocol. For plasma and cell supernatant, we used 
QIAgen’s miRNeasy Mini Kit for plasma RNA extraction with C. elegans miR-39 as spike-
in control. Total RNA concentration was assessed using a NanoDrop 2000 spectrophotometer 
(Thermo Fisher Scientific). For miRNA analysis, total RNA was diluted in RNAse-free water 
to a concentration of 2 ng/µL. Five µL (10 ng) was used for miRNA complementary DNA 
(cDNA) synthesis using the Taqman MicroRNA Reverse Transcription Kit with reverse 
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transcriptase primers for the selected miRNAs (Supplemental Table 6 and 7, all Thermo 
Fisher Scientific). For mRNA analysis, we used 200-1,000 ng of total RNA for cDNA 
synthesis using the Taqman High Capacity cDNA Transcription Kit with random primers. 
miRNA and mRNA expression was quantified by qPCR using Taqman FAM- or VIC-labeled 
miRNA and mRNA assays.  
2.2.8 miRNA OpenArray 
miRNA was purified from 200 µl plasma using the TaqMan miRNA ABC purification kit 
(Thermo Fisher Scientific, Human panel A and B).  ath-miR-159a oligo (synthesized by IDT, 
5'UUUGGAUUGAAGGGAGCUCUA3') was added into plasma as spike-in control. miRNA 
was stored at -80°C until use. The Megaplex primer human pools kit (Thermo Fisher 
Scientific) was used for miRNA reverse transcription, followed by pre-mplification using 
Taqman PreAmp Master Mix (Thermo Fisher Scientific). Vendor standard protocols were 
followed for these procedures.	
Samples were then diluted with 0.1×TE buffer, arranged into array order and applied to 
human miRNA panels using the OpenArray AccuFill system. Taqman OpenArray was 
performed on a QuantStudio 12K Flex Real-Time PCR system (Thermo Fisher Scientific). 
The resulting data was analysed using R software. Quality control included principal 
component analysis (prcomp in R) and analysis of data distribution (density in R). Expression 
of 758 individual miRNAs, including 4 endogenous controls, was tested in all samples. Ct 
values below 18 and above 38 were set to ‘undetermined’. To reduce technical variability, we 
used global normalization174; endogenous controls were removed from the dataset. 
2.2.9 Histology 
Mouse OCT-embedded frozen tissue was cut into 5 µm thick sections, dried and stored at  
-80°C. Human vascular material was sampled during surgery, fixed for 48 hours in 2% zinc-
paraformaldehyde at room temperature, paraffin-embedded and cut into 5 µm thick sections. 
Control arteries (carotid, radial, iliac or mammary) were obtained from deceased organ 
donors without any reported history of cardiovascular disease. Hematoxylin and eosin (HE) 
staining was used for basic tissue morphology. Lipids were stained with Oil Red O (Sigma-
Aldrich). For immunohistochemistry, we used standard biotin-streptavidin-horseradish 
peroxidase methods. 
2.2.10 In situ hybridization 
For in situ hybridization (ISH), we used Exiqon miRCURY LNA double digoxigenin (DIG)-
labelled probes with the accompanying kit and protocol (Exiqon). In brief, tissue sections 
were either de-paraffinized (FFPE) or thawed (frozen) and rehydrated. Nucleases were 
inactivated with Proteinase K followed by a two-hour hybridization at annealing temperature 
(30°C below RNA melting temperature). Slides were washed in saline-sodium citrate buffers 
before hybridized DIG-labelled probes were visualized with subsequent anti-DIG detection 
methods. Nuclear counterstaining was performed with Nuclear Fast Red (Sigma-Aldrich). 
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2.2.11 Western blotting 
Protein samples (15-30 µg/well) were loaded on Tris-Glycine gradient gels (all Thermo 
Fisher Scientific). Following electrophoresis and electrotransfer, the PVDF membrane (Bio-
Rad, Hercules, CA, USA) was blocked with 5% milk in Tris-buffered saline with 0.01% 
Tween (TBST) or 5% BSA-TBST (Bio-Rad) before incubation with primary antibody 
overnight at 4°C. After secondary antibody incubation, we used standard chemiluminescence 
detection methods and ImageJ analysis software to determine and quantify protein 
expression. 
2.2.12 Statistical analysis 
SPSS Statistics version 22 (IBM) was used to analyze patient data. To compare two groups, a 
Student’s t test was used. Paired data were analyzed by paired-samples t test. Differences 
between ≥2 groups versus a control group were analyzed with One-way ANOVA plus 
Bonferroni correction for multiple comparisons. Percentages and proportions were analyzed 
with Chi-square testing. Mann-Whitney U test was used to compare two groups when data 
were considered non-parametric. Statistical analysis for experiment data was carried out 
using R software, or Graphpad Prism software version 6.0b or higher. Differences in RNA 
expression were calculated as fold change versus control using the mean delta Ct (∆Ct, 
defined as Cttarget RNA minus Ctendogenous control or Ctglobal mean) within groups.  
In Project II, we used PASS software (Department of Biostatistics, College of Public Health, 
UNMC, Omaha, NE) to calculate the sample size needed to achieve 96% power for each 
miRNA, to detect a true difference in expression of at least 0.1 with estimated group standard 
deviations of 0.1 and with an experiment-wise error rate of 0.0500 using a two-sided two-
sample t test. We found a required sample size of 200 cases (patients with an abdominal 
aortic diameter (AAD) of >3 cm at baseline) and 150 controls (AAD <3 cm). Differences in 
RNA expression were calculated as fold change versus control using the mean ΔCt (defined 
as Cttarget RNA-Ctendogenous control or Ctglobal mean) within groups. The miRNA OpenArray results 
were analysed with One-Way ANOVA (control versus stable AAA versus AAArupt), and a 
Welch’s t test (AAA versus control). ANOVA was done with the R stats function aov (linear 
fitting) for each miRNA. Tukey’s post hoc test was performed on miRNAs with a significant 
ANOVA p-value after Bonferroni correction. ANOVA was executed as 
aov(Ct_norm~Group) where Group was a factor of the type of AAA (control/stable 
AAA/AAArupt). 
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2.3 RESULTS 
The following section includes a summary of results from the manuscripts constituting the thesis. 
For detailed results, please refer to the relevant paper. 
2.3.1 miR-24 in AAA (I) 
2.3.1.1 miRNAs in mouse AAA 
We compared miRNAs and mRNAs expressed in aneurysmatic abdominal aortic tissue from 
mice receiving porcine pancreatic elastase (PPE) infusion with those in tissue from sham-treated 
(saline-infused) mice. Of all the downregulated individual miRNAs, miR-24 had the most 
significant negative correlation with upregulated genes and in situ hybridization (ISH) showed 
diminished miR-24 expression throughout the aneurysmal aortic wall of PPE mice (Fig. 2.2A). 
Chitinase 3-like 1 (Chi3l1), a pro-inflammatory 18-glycosyl hydrolase produced and secreted by 
differentiated macrophages175, was the only miR-24 target gene substantially altered at day 7, 14, 
and 28 after PPE induction (Fig. 2.2B). 
In another AAA model of systemic angiotensin II (ANGII) infusion into Apoe-/- mice over a time 
course of 28 days, miR-24 was again significantly downregulated at all three time points (days 7, 
14 and 28) during aneurysm development (Fig. 2.2C), and Chi3l1 expression correlated 
negatively with miR-24 expression (Fig. 3.1.2c). ISH for miR-24 and immunohistochemistry 
(IHC) using a mouse macrophage antibody (F4/80) revealed that miR-24 co-localized with 
activated macrophages in aortic aneurysmal mouse tissue (post-PPE day 7; Fig. 2.2E). Double 
immunofluorescence of the vascular smooth muscle cell (SMC) marker alpha actin (α-SMA) and 
F4/80 with CHI3L1 indicated co-localization (orange in merged images) of CHI3L1 with SMCs 
as well as macrophages. In vitro experiments with peritoneal macrophages harvested from 
ANGII-AAA mice as well as RAW 264.7 macrophages showed a decrease in miR-24, affecting 
Chi3l1, dependent on IL6 stimulation, confirming a negative correlation between inflammation 
and miR-24 expression. 
2.3.1.2 Regulation and modulation of miR-24 in vitro and in vivo 
To elucidate the mechanistic effects of miR-24 modulation in AAA, we transfected macrophages 
and SMCs in vitro with anti-miR-24 or pre-miR-24 under various inflammatory stimuli. These 
experiments confirmed that pro-inflammatory CHI3L1 expression was miR-24 dependent. In 
both in vivo models of AAA development, pre- and anti-miR-24 delivery regulated Chi3l1 
expression and, more importantly, prevented respectively augmented AAA expansion and 
rupture (Fig. 2.2F). 
2.3.1.3 miR-24 in human AAA 
The clinical relevance of miR-24 as a biomarker for AAA was assessed using human infrarenal 
aortic tissue from patients undergoing open AAA repair surgery versus non-dilated organ donor 
controls. As in our animal models, miR-24 was significantly downregulated and CHI3L1 
upregulated in human AAA tissue. miR-24 levels were not different for small or large AAAs, but 
tissue expression of CHI3L1 correlated positively with disease severity (Fig. 2.2F). In a similar 
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manner, plasma miR-24 expression was decreased in patients with AAA as compared to age- 
medication- and risk factor-matched controls. Patients with peripheral vascular occlusive disease 
did not express these changes in miR-24. Again, plasma miR-24 could not distinguish patients 
with small from those with large aneurysms, whereas CHI3L1 levels could (Fig. 2.2G). 
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Figure 2.1 miR-24 prevents experimental AAA growth through inhibition of chitinase 3-
like 1. (A) In situ hybridization for miR-24 in control aorta, sham and PPE 14 days after AAA 
induction. Bar, 400 µm. (B) miR-24 target gene expression at day 7 after PPE surgery. (C) miR-
23b-24-27b cluster expression in aortic tissue from mice treated with AngII compared to NaCl-
infused mice. (D) In aortic macrophages from PPE-treated mice, miR-24 co-stained with 
CHI3L1. (E) Different-sized aneurysms in PPE mice treated with miR-24 modulators. (F) In 
human aortic tissue, CHI3L1 expression increased with AAA size. (G) In plasma, CHI3L1 
protein could distinguish patients with large AAA from patients with small AAA, PVOD and 
healthy controls. *p<0.05 versus sham/controls. #p<0.05 versus controls/small AAA. 
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2.3.2 microRNAs as AAA biomarker (II) 
2.3.2.1 Plasma miR-99b-3p, -99b-5p, -141-3p, and -643 expression predicts AAArupt or 
expansion 
Expression of 754 miRNAs was assessed in 195 AAA patients versus 184 matched controls from 
the Dutch Second Manifestations of Arterial disease (SMART) cohort161. After Bonferroni 
correction for multiple comparisons, miR-99b-3p, miR-99b-5p, miR-141-3p, and miR-643 were 
significantly deregulated in plasma from patients with AAArupt (rupture or expansion requiring 
surgery) as compared to controls and those with stable AAA. miR-99b-3p and miR-643 were 
downregulated; miR-99b-5p and miR-141-3p were upregulated (Fig. 2.2A). There were no 
significantly different miRNAs in plasma from patients with AAA at baseline versus controls. 
2.3.2.2 miR-99b is deregulated in murine models of AAA 
In aortic tissue from mice subjected to PPE or angiotensin II infusion, miR-99b (-5p and -3p) 
were consequently downregulated at 7 and 14 days after treatment induction, making miR-99b-
3p the only miRNA in mouse tissue regulated in the same direction as in human plasma. 
2.3.2.3 miR-99b expression is altered in ruptured AAA 
In tissue explanted during surgery due to ruptured AAA, as compared to tissue from non-
ruptured controls, miR-99b expression was decreased (Fig. 2.2B). 
 
Figure 2.2. Plasma and tissue expression of miR-99b-3p was altered in AAA and AAArupt. 
(A), miRNA expression in plasma from AAA and AAArupt patients versus controls. **p<0.01; 
***p<0.001; ****p<0.0001 versus control. †p<0.05; ††p<0.01; †††p<0.001 versus AAA. 
Significance calculated in One-Way ANOVA; p values adjusted with Tukey’s post hoc test after 
Bonferroni correction. (B), Relative expression of miR-30b, -30c, -99b-3p, and -106b in tissue 
from AAA patients (ruptured and non-ruptured) versus control tissue. 
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2.3.3 miR-210 in atherosclerotic plaque stability (III) 
2.3.3.1 Human carotid artery miRNA and target profiling 
In plasma from BiKE, sampled at the carotid lesion site after clamping of the carotid artery, 
microarray analysis showed that out of 742 tested transcripts, miR-210 was the most 
substantially (1.5 fold) and significantly downregulated miRNA in 7 symptomatic versus 5 
asymptomatic patients. In peripherally sampled plasma, miR-210 was undetectable in the 
majority of samples, and there was no difference in expression levels between symptomatic and 
asymptomatic patients. 
To find a more accurate localization in order to define a potential role for miR-210 in plaques, 
we performed in situ hybridization for miR-210 in histologically graded ruptured versus stable 
plaque, using a grading method issued by the Atherosclerosis Council of the American Heart 
Association20. miR-210 was expressed in the intima-medial layer of healthy vessels and stable 
plaques, but not in that of ruptured lesions (Fig. 2.3A). Laser capture microdissection of fibrous 
cap tissue confirmed suppression of miR-210 in ruptured versus stable fibrous caps (Fig. 2.3B). 
A potential functional role for miR-210 regulation in fibrous caps was explored by examining 
deregulation of miR-210 target genes in previously published BiKE microarray datasets163. The 
well-known tumor suppressor gene APC caught our attention, having an important inhibitory 
function in canonical Wnt signaling, which in SMCs contributes to the balance between 
proliferation and apoptosis176,177 
2.3.3.2 miR-210 and APC are deregulated in murine models of carotid injury 
To gain mechanistic insight into the function of miR-210 in the vessel wall, we aspired to create 
a more controlled vascular injury setting in which we could measure miR-210 and its targets. To 
achieve this, we used two different murine models of carotid manipulation. First, we saw a 
decrease in miR-210 in rat carotid arteries injured with an endovascular balloon, as compared to 
the intact contralateral carotid (Fig. 2.3C). Concordant with miR-210 downregulation, Apc 
mRNA expression was increased in the critical two-week post-injury period of remodeling and 
neointima formation. 
We created a more advanced atherosclerosis setting, ligating and subsequently placing a cast 
around the right carotid artery of male Apoe-/- mice. This resulted in plaque formation in 100%, 
and subsequent plaque rupture in 58% of animals. In situ hybridization of ruptured versus stable 
carotid plaques showed a decrease in miR-210 expression specifically in the fibrous cap (Fig. 
2.3D), while whole vessel miR-210 expression, as measured with qRT-PCR, was not different. 
2.3.3.3 miR-210 mimics prevent murine carotid plaque rupture 
Having established an association between miR-210 and APC expression on one side, and plaque 
vulnerability on the other, we used the mouse plaque rupture model to investigate whether miR-
210 modulation can influence plaque stability and rupture rate. First, we confirmed that we could 
successfully deliver (scrambled) fluorescently labeled oligonucleotides, via intraperitoneal 
injection, in the vessel wall of treated carotid arteries (Fig. 2.3E). miR-210 inhibition using LNA-
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coupled anti-miR-210 did not significantly increase plaque rupture compared to scrambled 
control, but miR-210 mimics substantially decreased the rupture rate (Fig. 2.3F). 
In a series of experiments to assess RNA- and protein marker expression, we could show that 
miR-210 mimic therapy resulted in decreased APC in mouse carotids, increased SMC content, 
and prevention of SMC apoptosis. Treatment with miR-210 mimics did not change other 
atherosclerosis parameters such as cholesterol or triglyceride levels, or atherosclerosis 
development per se as assessed by aortic arch en face Sudan IV- and aortic root Oil Red O 
staining. 
2.3.3.4 miR-210 modulation affects APC expression and HCtASMC apoptosis in vitro 
Based on previous knowledge about endothelial cell layer insufficiency16 and the influence of 
fluid shear stress on fibrous cap (in)stability178, we asked whether exposure of human carotid 
artery smooth muscle cells (HCtASMCs) in vitro to physiologic (laminar) or pathologic 
(oscillatory) fluidic flow would alter miR-210 and APC expression. When exposed to 12 
dyn/cm2 of oscillatory flow, HCtASMCs showed loss of miR-210 expression and upregulation of 
APC (Fig. 2.3G).  
In subsequent in vitro experiments, we could confirm our in vivo findings that miR-210 mimics 
inhibit APC protein expression and apoptosis. In addition, we explored the downstream effects of 
APC modulation on Wingless-related integration site (Wnt) signaling in HEK293 cells and 
HCtASMCs. In canonical Wnt signaling, APC is part of a destruction complex preventing β-
catenin from entering the nucleus, a translocation necessary to co-activate proliferative 
transcription factors including the T-cell factor/lymphoid enhancer factor (TCF/LEF) family179. 
In HEK293 cells as well as HCtASMCs, miR-210 mimics stimulated TCF/LEF signaling, an 
effect that was abolished by APC overexpression. Taken together, our in vitro findings point 
towards miR-210 as a crucial regulator of advanced atherosclerotic lesion fate by stimulating 
canonical Wnt signaling via inhibition of APC in SMCs (Fig. 2.3H). 
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Figure 2.3. miR-210 in atherosclerotic plaque stability. A, miR-210 expression associated 
with carotid smooth muscle as well as endothelial cells. APC co-localized with smooth muscle 
cells in ruptured, but not stable, plaques. B, LCM of carotid fibrous caps showed significantly 
decreased miR-210 and increased APC mRNA in ruptured versus stable plaques. Mean+SEM. 
*p<0.05 in Student’s t test, n=10 per group. C, During the first two weeks after balloon injury, 
rat carotid tissue showed inverse regulation of miR-210 and Apc mRNA. Mean+SEM. 
***p<0.001; **p<0.01; *p<0.05 in paired-samples t test. D, As in human lesions, miR-210 
localized towards the fibrous cap, and is associated with SMCs. Bars, 100 µm. 
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Figure 2.3 continued. E, FAM-labeled miRNA modulators were detected in the tunica media 
of carotid arteries where plaque rupture was induced. Bars, 100 µm. F, Intravenous 
administration of miR-210 mimics significantly reduced mouse carotid plaque rupture 
compared to scrambled miRNA and anti-miR-210 plaque rupture rate. **p<0.01, *p<0.05 in 
Chi2 test. G, Oscillatory (osc, pathologic) shear stress resulted in downregulation of miR-210 
in human carotid artery smooth muscle cells (SMC) as compared to laminar (lam, physiologic) 
shear stress. miR-210 expression remained unchanged in response to shear stress alteration in 
human carotid artery endothelial cells (EC). Mean+SEM. *p<0.05 in One-way ANOVA versus 
static control. H, Descriptive cartoon of the proposed mechanism of miR-210 dependent 
inhibition of APC-mediated apoptosis. 
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2.3.4 miR-29b and miR-146b in radiation-induced vascular inflammation (IV) 
2.3.4.1 miR-29b and miR-146b, and targets linked to inflammation and wound repair, are 
deregulated in radiated versus non-radiated vascular tissue 
In 15 pairs of arterial tissue samples from 15 patients undergoing microvascular free tissue 
transfer reconstructions after radiation for tumors in the head and neck area, we compared the 
expression of 11 well-known miRNAs in cardiovascular disease, cancer, or both. miR-29b and 
miR-146b were significantly deregulated in irradiated tissue (Fig. 2.4A). In situ hybridization of 
miR-29b and miR-146b in these arteries corresponded with the whole-vessel expression of both 
miRNAs. miR-29b and miR-146b could be found throughout the vessel wall, but with a clear 
predilection for the medial layer (Fig. 2.4B). 
Using previously published RNA analyses of these samples, we searched for experimentally 
validated miR-29b and miR-146b gene targets regulated in a direction inverse to that of the 
miRNA. In radiated versus non-radiated tissue, pentraxin 3 (PTX3) was the most profoundly 
upregulated miR-29b target. Dipeptidyl-peptidase 4 (DPP4) was also significantly upregulated. 
In immunohistochemically stained formalin-fixed paraffin-embedded arterial tissue from the 
same patients, we could localize PTX3 and DPP4 protein expression in the intimal and medial 
layer of radiated arteries, whereas expression in their non-radiated counterparts was markedly 
lower (Fig. 2.4B). 
2.3.4.2 Radiation affects vascular miR-29b and miR-146b expression in a murine model 
We subjected male Apoe-/- mice to radiation using a model first described by Stewart et al180. In 
mice receiving a single radiation dose of 14 Gy in a designated mediastinal area including the 
heart and large vessels, thoracic aortic- and carotid tissue showed significant downregulation of 
miR-29b after three days (carotid) and 14 days (thoracic aorta) (Fig. 2.4C-D). miR-146b showed 
an upward, albeit non-significant, trend. 
2.3.4.3 In SMCs, miR-29b reacts to radiation in vitro, and its modulation alters the cellular 
response to radiation 
When exposed to 2×2 Gy of radiation, miR-29b expression in SMCs decreased (Fig. 2.4E). 
Treating these cells with either miR-29b mimics or anti-miR-29b, we could change the gene 
expression of PTX3 (Fig. 2.4F). DPP4 gene expression was not directly affected but DPP4 
protein expression was – this is a common phenomenon in miRNA research where an mRNA is 
rendered inactive by the miRNA but still detectable with PCR. 
2.3.4.4 miR-29b modulation changes DPP4 and PTX3 expression in mouse vascular tissue 
In radiated mice, we found that treatment with miR-29b mimics decreased DPP4 and PTX3 
protein expression in the atherosclerotic plaque (DPP4) and vessel wall (PTX3) (Fig. 2.4F). 
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Figure 2.4. Irradiation affects arterial miR-29b and miR-146b expression in human 
arteries. A, miR-29b is downregulated, miR-146b upregulated after irradiation. n=15 in each 
group. *p<0.05: ***p<0.001 in paired-samples t test. B, both miRNAs localize towards the 
tunica media. C and D, miR-29b is significantly deregulated in irradiated mouse tissues versus 
tissue from sham-irradiated mice. Mean±SEM. E, human carotid artery SMCs (HCtASMCs) 
downregulate miR-29b after irradiation. F, HCtASMC PTX3 mRNA expression can be changed 
with miR-29b modulators. Mean+SEM; *p<0.01; ****p<0.0001 in Student’s t test. G, DPP4 and 
PTX3 protein expression in scrambled control- (scr) versus miR-29b mimic treated mice. Bars, 
100 µm. 
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3 DISCUSSION 
Among the pharmacological approaches to battle atherosclerotic disease, traditional agents 
such as anti-hypertensives, statins, and platelet aggregation inhibitors have greatly improved 
patients’ clinical perspectives. Although these currently applied pharmaceuticals can alleviate 
symptoms of cardiovascular disease, they mainly interfere with specific early triggers of 
vascular remodeling (e.g. RAAS activation). As cardiovascular disease ought to be seen as a 
combined sequela of different inducing events (mechanical triggers, RAAS activation and 
inflammation), these strategies appear only partially effective. The incessant advance of 
cardiovascular disease worldwide, in the Western world especially due to ageing populations, 
demands therapies that more directly target the structural changes and alterations of vascular 
signaling underlying the process of remodeling, not only in early stages, but also in advanced 
disease. Furthermore, atherosclerosis leading to cardiovascular events needs to be better 
distinguished from vascular remodeling associated with normal ageing. The biological 
robustness miRNAs can add to a patient’s risk profile can help cardiovascular medicine to 
live up to the expectations of ‘personalized medicine’. 
The discovery of ncRNAs as critical contributors to gene expression and genome 
maintenance has initiated a surge in ncRNA research. As human genome banks expand, 
increasingly detailed information about the diversity of the RNA landscape becomes 
available, and in the present-day society these discoveries are readily presented as future 
groundbreaking medical advances. Indeed, it is increasingly difficult to find a biological 
process not influenced by ncRNAs; ncRNA therapeutics can target and modify cellular 
messages previously considered as ‘un-druggable’, and this understandably has sparked wide 
medical and economic interest in ncRNA modifying compounds. Yet, thus far, the modest 
number of clinical ncRNA successes does not reflect the auspiciousness of perspectives 
depicted in preclinical and in vitro studies. In our view, inability of the ncRNA field to live 
up to its promises is partly due to a lack of mechanistic translational studies, which combine 
patient data with in vitro and in vivo findings. Even more importantly, potential therapeutic 
ncRNA modifiers identified by translational studies need to be applied in vivo in a manner 
relevant to the targeted human pathology, for example locally, and by using safe as well as 
effective carriers. 
3.1 THE CURRENT PLACE OF NCRNAS IN CARDIOVASCULAR MEDICINE 
As biomarkers, miRNAs are at the forefront of the ncRNA domain, because their relative 
stability and co-expression patterns can provide a detailed signature of a disease. miRNAs 
can help to classify diseases, predict drug efficacy, and improve risk prediction. We showed 
that miR-24 and miR-99b levels in plasma can indicate AAA progression by reflecting the 
cellular state and behavior of aortic macrophages and SMCs. Use of these expression data 
adds vascular biological robustness to ultrasound measurements. This can provide a better 
prediction of AAA rupture and is therefore a step towards better allocation of AAA 
correction surgery. 
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The discordance between studies, the absence of proper normalizing controls, and the 
multitude of confounding factors such as medication, inflammation, and diet, are major 
remaining challenges in the candidacy of miRNAs as biomarkers85. For the field to overcome 
these issues, development of large-scale studies and standardization of detection methods are 
essential. In all studies, human material was the starting point for ncRNA expression analysis. 
Potential mechanisms behind the pathology were then tested in silico, in vitro and in vivo. 
3.2 MIR-24, MIR-210 AND MIR-29B IN SELECTED CARDIOVASCULAR 
DISEASES 
As therapeutic agents, ncRNAs can have potent effects on disease phenotypes in vitro and in 
vivo. First, we could show in mouse models of AAA as well as in human aortic SMCs that 
miR-24 has an essential role in macrophage inflammatory activity through inhibition of 
CHI3L1 (Paper I). In mice, interaction between miR-24 and Chi3l1 controlled inflammatory 
activity within the dilated aortic wall. Through enhanced blockage of Chi3l1 with pre-miR-
24, inflammatory activity was dampened, resulting in limited AAA expansion. In vitro 
experiments showed that NF-κB is partly responsible for miR-24 downregulation in SMCs 
exposed to inflammatory activity. In macrophages and SMCs, miR-24 downregulation 
stimulated cytokine synthesis and adhesion molecule expression, suggesting a locally acting 
vicious circle of inflammation, miR-24 downregulation, and AAA expansion. This local 
element in AAA pathology makes miR-24 and CHI3L1 interesting potential targets for drug 
eluting balloon- or stent-mediated expansion prevention. 
In Paper III, we found miR-210 to be strongly and significantly downregulated in and around 
unstable fibrous caps of carotid atherosclerotic plaques. In three different in vivo models of 
vascular injury, we confirmed the association of miR-210 with arterial remodeling and 
unstable plaque. Using systemically injected miR-210 mimics, we successfully inhibited 
apoptosis of SMCs, the source of fibrous cap-associated miR-210, by blocking the tumor 
suppressor gene APC in these cells. We showed in vitro that SMCs can be rescued from 
apoptosis through miR-210 overexpression causing enhanced posttranscriptional inhibition of 
APC. APC inhibition leads to stimulation of canonical Wnt signaling, which in SMCs can 
direct a variety of atherosclerotic processes, e.g. proliferation, cell migration, differentiation 
and apoptosis, leading to a stable plaque phenotype. A point of concern regarding miR-210 is 
the reported link between high miR-210 expression with various forms of cancer181. Our 
findings identifying miR-210 as inhibitor of one of the most infamous cancer genes, add to 
this evidence. To prevent potentially tumorigenic off-target effects, plaque-stabilizing miR-
210 therapy should ideally be applied locally with stents or balloons. 
In radiated SMCs, we inhibited PTX3 production and collagen synthesis by increasing the 
availability of miR-29b, a miRNA able to target PTX3 and thereby development of fibrosis 
(Paper IV). PTX3 is a direct actor in innate inflammation, and its inhibition with the use of 
miR-29b mimics could be a potent therapeutic approach to thwart radiation-induced 
vasculopathy. 
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The fact that some miRNAs are tissue specific has advantages for their diagnostic and 
therapeutic application, but only a minority of miRNAs shows tissue specificity182. We and 
others have demonstrated that systemic delivery of miRNA mimics or anti-miRs presents a 
considerable load of these modulators to the circulation, where they might interact with 
serum proteins, accumulate in organs such as the kidney, liver and lungs, and possibly also 
exert adverse off-target effects at these sites102,183. Local application, allowing lower dosages 
and preventing distant off-target effects, increases safety as well as efficiency. Developing 
new targeted delivery methods with the use of nanoparticles, conjugates, targeting ligands et 
cetera has become a rapidly expanding field of research, where innovative and creative 
designs are met with great academic as well as financial interest. 
The inhibitory effect of a miRNA on one mRNA is often modest, but this fact is compensated 
by the multiplicity of mRNA targets one miRNA can have. Examples are miR-29, which has 
multiple targets in the fibrotic response110, and miR-145, which regulates components of actin 
cytoskeletal function184. This pleiotropic character, although biologically efficient, 
complicates miRNA therapy strategies and further stresses the importance of local 
distribution of miRNA modifiers if they are to be applied as treatment. 
3.3 MIR-99B AS BIOMARKER FOR AAA 
In Paper II, we showed that plasma miR-99b expression can, in a population at risk for 
vascular disease, distinguish between individuals with normal caliber aortas, stable AAA and 
rupture-prone aneurysms. In addition, miR-99b deregulation was observed in aortic tissue 
from patients with ruptured AAA. That the expression of this miRNA is also distorted by 
AAA induction in mice, suggests a role for miR-99b in the inflammatory process underlying 
AAA. Downregulation of miR-99b might be involved in extracellular matrix breakdown, 
when the inhibitory actions of this miRNA on tumor growth factor-beta (TGF-β)-induced 
epithelial to mesenchymal transition are thwarted. 
3.4 FUTURE PERSPECTIVES 
The number, quality and reproducibility of translational studies will ultimately determine the 
success of ncRNA therapeutics for human disease. Application of ncRNAs, identified in 
silico and in vitro, in in vivo disease models is an essential step in translation. This research 
strategy, when applied, will undoubtedly also unveil the challenges in developing ncRNA 
therapeutics: delivery method, pleiotropy, and stability. 
For cardiovascular disease, coated stents or balloons lend themselves readily for miRNA 
delivery102,185, and this possibility should be explored in large animal models, if not clinically. 
Ultrasound-triggered microbubbles face a longer path towards clinical application, but their 
non-invasive properties are attractive features in the vulnerable cardiovascular patient 
group186. 
The future for clinical application of ncRNAs lies in the discovery of more in-depth 
knowledge of the different ncRNAs and their function, better detection methods and higher 
 40 
efficacy and specificity of ncRNA therapeutics. Another important task for the ncRNA field 
is to draw attention to the message that ncRNAs, like proteins, are essential functional cell 
elements, and that in cellular biology, cooperation between RNA and proteins is a rule rather 
than an exception. Only this perspective, which fundamentally differs from the unidirectional 
‘central dogma of molecular biology’, does justice to the pivotal role of ncRNAs in health 
and disease. 
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4 CONCLUSION 
In this thesis, we used human material to detect ncRNAs marking and regulating the 
discourse of three cardiovascular diseases. In vivo, we found that modulation of selected 
ncRNAs can be used to direct cardiovascular pathologic processes towards a protective, 
disease-limiting phenotype. Reducing the vascular pathology in vitro to biological processes 
involving different human cell types such as SMCs, ECs and macrophages, we found 
miRNA-mRNA interactions that explain the behavior of vascular cells, not only in these 
specific diseases, but in atherosclerosis in general. With this work, we have contributed 
evidence to the notion that ncRNAs are essential cellular elements, equaling proteins in 
importance and potency. Given the proven clinical potential of siRNA-based ncRNA-
modifying techniques, and in line with the recent surge in siRNA delivery techniques, 
ncRNA therapies for cardiovascular disease are becoming near-future therapeutic options, 
rather than distant prospects. 
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